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%SE  percent of standard error 
AKI  acute kidney injury 
ALT  alanine aminotransferase 
APACHE II acute physiology and chronic health evaluation II score 
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Sepsis – a systemic, deleterious host response to infection – and its most 
complicated forms, severe sepsis (acute organ dysfunction secondary to docu-
mented or suspected infection) and septic shock (severe sepsis plus hypotension 
not reversed with fluid resuscitation) (Dellinger et al. 2013), remain a major 
healthcare problem (Angus et al. 2013). The incidence of severe sepsis is rising 
(Brun Buisson et al. 2004). Although mortality has decreased during the last 
decade, it still remains high (Brun Buisson et al. 2004, Dombrovskiy et al. 
2007). Acute renal failure, often occurring as a complication of severe sepsis, is 
an independent risk factor of death (Brun Buisson et al. 2004). 
The key issues in the treatment of sepsis are adequate antibacterial therapy, 
rapid source control and handling of the dysbalance between pro- and anti-
inflammatory forces. Delay in initiating antibacterial treatment or inadequate 
choice of antibiotics have been shown to lead to increased mortality in septic 
patients (Kumar et al. 2006). Control of pro- and anti-inflammatory forces is 
equally important, but difficult to achieve due to the highly complicated nature 
of the reaction and huge number of mediators involved. During the last fifteen 
years nonselective extracorporeal removal of mediators using renal replacement 
therapies (RRT) has been suggested as beneficial in restoring immuno-
homeostasis (Ronco et al. 2004). Removal of middle size molecules i. e. cyto-
kines depends on the modality of the RRT, but also on the filter characteristics 
and the volume of therapy (Ricci et al. 2006a, Cerda et al. 2009). Clinical and 
experimental data show improved survival of septic patients with renal failure 
with increasing dose of RRT (Honore et al. 2000, Schiffl et al. 2002, Cornejo et 
al. 2006, Bouman et al. 2007). Still some controversy exists as a randomised 
controlled trial failed to confirm this effect (Joannes-Boyau et al. 2013). Pre-
liminary results from Kron and colleagues suggested that high volume 
haemodiafiltration (HVHDF) with specific Ultracontrol mode technique is 
associated with superior survival compared to survival predicted by disease 
severity scores (Kron et al. 2011). Unlike the standard pressure and volume 
control, the Ultracontrol mode of filtration titrates the transmembrane pressure 
during the diafiltration so, that optimal conditions (highest filtrate volume at the 
lowest possible transmembrane pressure) are achieved and maintained. Use of 
ultrapure water supplemented with electrolytes instead of incased replacement 
solutions makes the technique feasible – the costs are almost equal to the inter-
mittent technique (Kron et al. 2011). 
While potentially effective in restoring immunohomeostasis, high filtration 
volumes may lead to excessive removal of antibiotics and ineffective plasma 
and tissue concentrations of the vitally important drugs, thus decreasing or 
eliminating the clinical benefits (Jamal et al. 2014b). On the other hand, un-
controlled increase in dosing may result in toxicity (Roberts DM et al. 2012). 
The pharmacokinetics (PK) of β-lactam antibiotics has been studied during 
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different methods of RRT, used in septic patients, and significant, RRT dose 
dependent elimination has been shown (Jamal et al. 2014b). 
The present thesis studies the impact of a specific mode of HVHDF – the 
predilution Ultracontrol – on the PK of two β-lactam antibiotics, and explores 
the patients’ circulatory parameters and inflammatory mediators in response to 
this treatment.  
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2. REVIEW OF LITERATURE 
2.1 High volume haemo(dia)filtration 
In current practise different methods of RRT are used in critically ill patients 
(Mehta et al. 1999, Ronco et al. 2001, Ricci et al. 2006b, Overberger et al. 2007, 
Gatward et al. 2008, Legrand et al. 2013, Jamal et al. 2014a, Iwagami et al. 
2015). Solute clearance can be achieved either by diffusion (haemodialysis, 
HD), convection (haemofiltration, HF) or the combination of both (haemodia-
filtration, HDF) (Fig. 1) (Pannu et al. 2008). The volume of replacement fluid 
used determines whether the method in use can be defined as high volume HF 
or HDF. While small molecules diffuse rapidly and are efficiently removed by 
haemodialysis, the clearance of middle-sized molecules, such as beta-2-
microglobulin and cytokines is believed to be better via haemofiltration 
(DeVriese et al 1999, Cerda et al. 2009). All these methods can be performed 
continuously, intermittently or in hybrid forms like sustained low efficiency 
dialysis (SLED) or extended daily dialysis, where the intermittent procedure is 
extended to more than 10 hours per day (Palevsky et al. 2013 ). Continuous 
renal replacement therapy is the most common form used in critically ill 
patients, although hybrid forms are becoming more widely used (Vesconi et al. 
2009, Jamal et al. 2014a). 
 
2.1.1 Definition of high volume haemofiltration 
High volume haemofiltration (HVHF) is not well defined in medical literature. 
Different definitions exist, resulting in the situation, that the high volume group 
in some studies may be the low volume group in others (Rimmele et al 2012). 
The conventional filtration volumes, used in critically ill septic patients are  
24–35 mL/kg/h (Borthwick et al. 2013), thus, HVHF was initially defined as 
continuous haemofiltration with ultrafiltration volumes greater than 35 mL/kg/h 
(Kellum et al. 2002). This definition has been used as late as 2013 (Borthwick 
2013). At present, the most frequently used definition is the Pardubice 
definition, defining HVHF as continuous high-volume treatment of more than 
50 ml/kg/h for 24 h per day and intermittent high-volume haemofiltration with 
brief, very high-volume treatment at 100–120 ml/kg/h for a short period of 4–
8 h, followed by conventional continuous veno-venous haemofiltration (CVVHF) 
(Honore et al. 2007). Not all definitions of intermittent HVHF incorporate the 
following conventional RRT method. The second edition of Critical Care 
Nephrology defines high volume hemofiltration as continuous high volume 
treatment, providing 50–70 mL/kg/h 24 hours a day, and intermittent hemo-
filtration with brief, very-high-volume regimens of 100–120 mL/kg/h for 4–8 




Figure 1. Principles of solute clearance in RRT. A. Haemodialysis. The mechanism 
of solute clearance is diffusion of solutes due to concentration gradient, created by 
countercurrent flow of blood and dialysate fluid. B. Haemofiltration. Solute clearance 
is achieved by convection due to hydrostatic pressure gradient, generated by dialysis 
machine across the filter membrane. Both water and solutes are filtered. To avoid 
excessive fluid loss via filtration, replacement fluid is administered. In postdilution 
mode (B, upper panel) replacement fluid is administered after the passage of blood over 
the filter. In predilution mode (B, lower panel) replacement fluid is administered before 
the passage of blood through the filter and dilutes the concentration of solutes on the 
filter. The efficiency of solute removal is reduced. C. Haemodiafiltration. Combines 
haemodialysis with haemofiltration, either with pre- or postdilution mode.  
4
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2.1.2 High volume haemofiltration for extracorporeal  
blood purification in severe sepsis and septic shock 
Persistently elevated levels of inflammatory markers have been shown to be 
associated with RRT dependence and death in patients with severe sepsis and 
septic shock (Payen et al. 2012, Murugan et al. 2014, Murugan et al. 2015). 
Since the landmark study by Ronco et al. (Ronco et al. 2000), where better 
survival of critically ill patients with acute kidney injury (AKI) was found with 
filtration volumes of 35 mL/kg/ h or 45 mL/kg/h, compared to 20 mL/kg/h, 
higher filtration volumes have been used in septic patients in the hope of 
removing excess pro- and anti-inflammatory mediators and restoring immuno-
homeostasis. Despite that two large multicentre randomised trials, comparing 
filtration volumes of 20 mL/kg/h to 35 mL/kg/h (VA/NIH Acute Renal Failure 
Trial Network 2008) and 25 mL/kg/h to 40 mL/kg/h (RENAL Replacement 
Therapy Study Investigators 2009) did not observe survival benefit, the concept 
of extracorporeal blood purification in the treatment of sepsis has remained 
attractive (Ronco et al. 2015). 
Animal studies have shown reversal of sepsis or severe acute pancreatitis 
induced hypotension and decrease in cardiac output by haemofiltration with 
doses exceeding 50 mL/kg/h (Grootendorst et al. 1992, Grootendorst et al. 
1994, Rogiers et al. 1999, Bellomo et al. 2000, Yekebas et al. 2001, Li et al. 
2013) with more pronounced effect with increasing filtration volumes (Rogiers 
et al. 1999).  
Clinical studies with high volume haemofiltration are summarised in 
Table 1. Prospective clinical series with filtration volumes exceeding 50 mL/kg/h 
in patients with septic shock, refractory to conventional treatment suggested 
decrease of noradrenaline requirements, stabilisation of haemodynamics and 
improved survival compared to that predicted by disease severity scores 
(Oudemans-van-Straaten 1999, Honore et al. 2000, Joannes-Boyau et al. 2004, 
Cornejo et al. 2006, Ratanarat et al. 2006, Kron et al. 2011, Tapia et al. 2012). 
High volume haemofiltration was proposed as salvage therapy in intractable 
septic shock (Honore et al. 2000, Cornejo et al. 2006).  
Subsequent randomised clinical trials (RCT-s) reached controversial results. 
Cole and colleagues compared 8 hour high volume HVHF to 8 hour standard 
CVVHF and found greater reduction in noradrenaline requirements in the 
HVHF group (Cole et al. 2001). Some following single centre randomised 
trials, comparing either pulse or continuous HVHF to standard dose RRT in 
patients with septic shock or acute pancreatitis showed improved haemo-
dynamics but no survival benefit (Boussekey et al. 2008, Peng et al. 2010, Chu 
et al. 2013). Other randomised trials have shown no haemodynamic or survival 
benefit in patients with severe sepsis or septic shock (Bouman et al. 2002, 
Ghani et al. 2006, Sanchez et al. 2010, Zhang et al. 2012). Škofic and 
colleagues compared intermittent high volume online haemofiltration to inter-
mittent haemodialysis in critically ill patients with AKI and found no dif-
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ferences in mortality between the two groups (Škofic et al. 2012). The biggest 
multicentre randomised controlled study, comparing CVVHF in doses of 35 
mL/kg/h to 70 mL/kg/h was conducted in 18 ICU-s in France, Belgium and the 
Netherlands. No difference was demonstrated in the primary endpoint of 28-day 
mortality between the groups. Neither were there any differences in haemo-
dynamic profile, organ failure scores, recovery of renal function, ICU or 
hospital stay, 60- and 90-day mortality or adverse events, attributable to RRT 
(Joannes-Boyau et al. 2013). Yet the study was underpowered, recruiting only 
30% of the required sample size (Joannes-Boyau et al. 2013). 
A Cochrane database systematic review included three randomised 
controlled studies and concluded that there was very weak evidence to support 
the use of HVHF in critically ill patients with severe sepsis/septic shock to 
improve outcomes and that there was no evidence to suggest the treatment 
intervention was harmful (Borthwick et al. 2013). Another meta-analysis of four 
randomised trials reached similar conclusion, namely that there was insufficient 
evidence of a therapeutic benefit for routine use of HVHF for septic AKI, other 
than on an experimental basis (Clark et al. 2014). 
In summary, different methods and doses of HVHF have been studied in 
different patient groups with controversial results. Although RCT-s have not 
shown clinical benefit from HVHF, individual patients might still benefit from 
higher doses of RRT, when hypercatabolic states or sepsis are present (Ronco et 
al. 2015). A personalised approach, mapping RRT intensity to biomarker levels 
could be effective (Ronco et al. 2015). The evidence, if and which patient 
groups would benefit from HVHF remains inconclusive.  
 
Table 1. Clinical studies evaluating the effect of HVHF in treatment of SIRS and shock. 
Author 
year 
Study type Patients, No. Method of RRT Main results 








All ICU patients, 




sepsis 67%, 306 
Intermittent HVHF 
UF 5 L/h, 
postdilution 
Aim 100 L per 
procedure 
Mortality lower than 







Severe septic shock 






and metabolic response. 
Mortality lower than 
predicted. Survivors 
received higher UF dose 










HVHF UF  
40–60 mL/kg/h 
Haemodynamic 
improvement. Decrease in 
noradrenaline requirement 







Severe septic shock 




Qu 100 mL/kg/h 
Haemodynamic 
improvement. 









Pulse daily  
HVHF Qu 
85 mL/kg/h 
Decrease in noradrenaline 
requirement 

















Severe septic shock 








Decrease in noradrenaline 
requirement 






Study type Patients, No. Method of RRT Main results 









(Qu 7.8 L/h) vs no 
RRT 
Substantial amounts of 
TNF-α and IL-6 in 
ultrafiltrate, no difference 
in serum concentrations 






HVHF (Qu 6 L/h) 8 
h vs conventional 
HF (Qu 1 L/h) 8 h 
Greater reduction in 
noradrenaline requirement 
in HVHF group 
Greater reduction in 













48 mL/kg/h) vs 
early LVHF 
(median Qu 
20 mL/kg/h) vs late 
LVHF (median Qu 
19 mL/kg/h) 
No benefit in terms of 28-






Severe sepsis and 
septic shock 
33 
HVHF (6 h, Qu  
100 mL/kg/h) vs 
conventional HF 
(Qu 35 mL/kg/h) 










Qe 2.5–4 L/h vs 
CVVHF  
Qu 1–2.5 L/h 
Increased 28-day and 90-









65 mL/kg/h) vs 
standard HF (Qu  
35 mL/kg/h) 
Greater reduction in 
noradrenaline requirement 





Pulse HVHF (Qu  
85 mL/kg/h) for 72 
h vs conventional 
HF (Qu 35 mL/kg/h)
Greater reduction in 
noradrenaline requirement 
in HVHF group, Greater 














CHVHF (Qu > 55 
mL/kg/h) vs 
conventional HF 
(Qu 35 mL/kg/h) 




groups 28-day survival 










(Qu 85 mL/kg/h) vs 
HVHF 
(Qu 50 mL/kg/h) 
No survival benefit at 28 or 
90 days. 












(median Qu 4.8 L/h) 
vs intermittent HD 
(Qd 500 mL/min) 
No difference in mortality 






Pulse HVHF (6 h, 
Qu 85 mL/kg/h), 
followed by con-
ventional CHF vs 
conventional CHF 
(Qu 35 mL/kg/h) 
Greater reduction in 
dopamine requirement in 
HVHF group 










CHVHF (Qu  
70 mL/kg/h) vs 
continuous SVHF 
(Qu 35 mL/kg/h) 
No difference between 
groups in terms of 28-day 
mortality, haemodynamic 
stabilisation or organ 
function 
CHF – continuous haemofiltration, CHVHF – continuous high volume haemofiltration, CVVHDF – 
continuous high volume haemodiafiltration, EHVHF – extra high-volume haemofiltration, HD – 
haemodialysis, HF – haemofiltration, HVHF – high volume haemofiltration, IL-6 – interleukin-6, LVHF – 
low volume haemofiltration, Qd – dialysate flow rate, Qe – effluent flow rate (ultrafiltrate + dialysate flow 
rate), Qu – ultrafiltrate flow rate, SVHF – standard volume haemofiltration 
Table 1. Continuation
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2.1.3 Removal of pro- and anti-inflammatory mediators  
by high volume haemofiltration 
High volume haemofiltration is an attractive therapy to remove a wide range of 
pro- and anti-inflammatory molecules that play an important role in the 
pathogenesis of sepsis (Rimmele et al. 2012). These mediators are mostly water 
soluble, circulating freely in plasma and have molecular mass ranging from 5 
kDa to 60 kDa. Molecules below the haemofiltration membrane cut-off will be 
filtrated through the membrane together with water and other solutes (Rimmele 
et al. 2012). Convection is more effective in removing middle molecules than 
diffusion (De Vriese et al. 1999, Kellum et al. 1998, Cerda et al. 2009). In 
addition, most haemofiltration membranes have some adsorptive capacities and 
mediators with molecular weight above the membrane cut-off may be adsorbed 
on the membrane (Rimmele et al. 2012). 
Animal studies have shown that mediators are filtrated through the haemo-
filtration membrane as the ultrafiltrate from septic animals induces haemo-
dynamic changes similar to septic shock and even death when infused to 
healthy animals (Grootendorst et al. 1993, Lee et al. 1993, Rogiers et al. 1999). 
It is not very clear, which cytokines are removed most effectively. Yekebas et 
al. measured substantial amounts of TNF-α and IL-10 in ultrafiltrate in porcine 
pancreatitis model (Yekebas et al. 2001), while other studies found very low 
levels or no TNF-α in ultrafiltrate (Rogiers et al. 1999, Bellomo et al. 2000). A 
recent meta-analysis of animal studies reached the conclusion that HVHF, but 
not standard RRT has the potential to achieve appreciable IL-6 and IL-10, but 
not TNF-α clearances (Atan et al. 2013a). 
The results of human studies are similarly controversial. Not many studies 
have measured cytokine concentrations in plasma or ultrafiltrate. Some human 
studies have shown significant decrease in plasma cytokine concentrations in 
patients treated with HVHF, namely IL-10 (Cole et al. 2001), IL-6 (Ghani et al. 
2006) or TNF-α, IL-1, IL-4, IL-6 and IL-10 (Peng et al. 2010) in patients with 
severe sepsis, and TNF-α, IL-6 and IL-10 in patients with severe acute 
pancreatitis (Chu et al. 2013). Sanchez-Izquierdo et al. found substantial 
amounts of TNF-α and IL-6 in ultrafiltrate in critically ill trauma patients, but 
no significant decrease in serum cytokine levels and no difference compared to 
not HVHF treated controls (Sanchez- Izquierdo et al. 1997). A recent 
metaanalysis of human studies concluded that neither standard nor high volume 
haemofiltration with conventional haemofilters are able to significantly remove 
cytokines (Atan et al. 2013b). Only two studies of HVHF (Sanchez-Izquierdo et 
al. 1997, Cole et al. 2001) were included in the analysis (Atan et al. 2013b). In 
addition to cytokines other inflammatory mediators like prostaglandins and 
leukotrienes (Yokoyama et al. 2009), complement factors (Cole et al. 2001) and 
myocardial depressant factors (Blake et al. 1996) can be removed by HVHF. 
Adsorption of cytokines to the haemofilter is considered an important 
mechanism of cytokine removal by haemofiltration (Honore et al. 2013). 
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Membranes with higher adsorptive capacities are more effective in cytokine 
removal, despite their lower cytokine filtration rates (Hirayama et al. 2011). 
Polyacrylonitrile or polymethyl metacrylate (PMMC) membranes exhibit most 
adsorptive capacities (Honore et al. 2013). For polyarylethersulfone (PAES) 
filters, removal of small molecular-weight proteins with molecular mass up to 
24 kDa via both filtration and adsorption has been shown (Ouseph et al. 2008). 
Several hypotheses have been proposed to explain the possible haemo-
dynamic effects of HVHDF. The “peak concentration hypothesis” suggests that 
haemofiltration, applied in the early phase of sepsis eliminates the peaks of both 
anti- and proinflammatory cytokines, thus restoring immunohomeostasis 
(Ronco et al, 2004). The hypothesis stresses the importance of applying haemo-
filtration early in the course of the disease. Another, the “active transportation 
between two asymmetric compartments” hypothesis (Honore et al. 2012a), 
combining the “threshold immunomodulation hypothesis” (Honore et al. 2004) 
and the “mediator delivery hypothesis” (Di Carlo et al. 2005) postulates, that 
removal of cytokines from blood leads to increased gradient and therefore 
increased removal from tissues, thus limiting the systemic inflammation at 
tissue level. In addition to passive transportation, HVHF induces increase in 
lymphatic flow due to high amounts of crystalloids used as replacement fluids, 
which leads to significant drag and displacement of the cytokines to blood 
compartment, making them available for extracorporeal removal. This 
hypothesis explains why numerous studies failed to show significant decrease in 
cytokine plasma concentrations, as cytokines from tissues replace those, removed 
from blood compartment. The “cytokinic” theory suggests that removing 
inflammatory mediators from plasma increases concentration gradient from 
plasma to infected tissues, resulting in leucocyte homing to the nidus of 
infection instead of passing into the blood, thus increasing bacterial clearance 
locally and limiting remote organ damage (Namas et al. 2012, Honore et al. 
2012b). 
 
2.1.4 Effect of high volume haemodiafiltration  
on tissue perfusion 
The effect of HVHF on microcirculation and tissue perfusion is not clear. 
Increase of blood pressure, if achieved via vasoconstriction, may theoretically 
lead to impaired tissue perfusion. An animal study found HVHF to be effective 
in reversing sepsis-induced hypotension, but not disturbances in microvascular, 
metabolic, endothelial and lung function (Sykora et al. 2008). Some human 
studies have reported increase in cardiac index with isovolemic HVHDF 
(Honore et al. 2000, Tapia et al. 2012), while others have concluded that 
increase of blood pressure occurs due to increased vascular resistance rather 
than increased cardiac output (Cornejo et al. 2006). Based on serum lactate 
levels as surrogate markers of tissue perfusion, HVHF seems to improve tissue 
metabolism as reflected by decreased serum lactate levels (Honore et al. 2000, 
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Cole et al. 2001, Cornejo et al. 2006). Although lactate removal by RRT 
corresponds to lactate concentration in plasma times millilitres filtrate per minute, 
it is only a fraction of lactate production, which is about 14 mmol/kg/min 
(Bollmann et al. 2004). Thus, the decrease in lactate more likely reflects 
improved circulation (Oudemans-van Straaten et al. 2013). Sublingual micro-
circulation during HVHF has been studied in 12 patients in severe hyper-
dynamic septic shock and no deterioration of microcirculation has been found 
despite increase in systemic vascular resistance (Ruiz et al. 2010).  
In summary, HVHF seems to have a blood pressure stabilizing effect with 
possible improvement of tissue perfusion, at least in patients with refractory 
septic shock. Whether the effect is due to removal of pro- or anti-inflammatory 
cytokines or other substances, remains unclear. 
 
 
2.2 Pharmacokinetics and pharmacodynamics  
of β-lactam antibiotics in septic patients  
with acute kidney injury 
Beta-lactams (penicillins, cephalosporins and carbapenems) are the most 
commonly prescribed family of antibiotics (Roberts et al. 2014b). Their broad 
spectrum of activity and wide therapeutic window allows them to be widely 
used as empiric therapy in intensive care units (Cotta et al. 2014). Carbapenems 
and β-lactam/β-lactamase inhibitor combinations (BLBLIs) are used to treat 
infections caused by bacteria, resistant to other antibiotics, such as ESBL 
producing enterobacteria or Pseudomonas (Harris et al. 2015). While it has been 
shown that optimal exposure to β-lactams has positive effect on clinical cure 
and/or mortality of patients with severe sepsis and septic shock (Li et al. 2007, 
Scaglione et al. 2009, Crandon et al. 2010, Roberts et al. 2010b, Muller et al. 
2013, Roberts et al. 2014c), adequate exposure is difficult to achieve in this 
patient population due to changes in pharmacokinetics and high inter-patient 
variability. Several studies have found that commonly used dosing regimens 
result in inadequate plasma concentrations of β-lactam antibiotics in critically ill 
patients undergoing RRT (Seyler et al. 2011, Roberts DM et al. 2012, Roberts et 
al. 2014c). Fluid extravasation due to capillary leak and fluid resuscitation may 
lead to substantial increase in volume of distribution (Goncalves-Pereira et al. 
2011, Sime et al. 2012), potentially causing inadequate plasma concentrations at 
the beginning of antibacterial therapy, especially of hydrophilic antibiotics like 
β-lactams (Goncalves-Pereira et al. 2011, Sime et al. 2012). Achieving adequate 
antibiotic concentrations at the site of infection might further be delayed due to 
disturbances of microcirculation leading to impaired tissue penetration of the 
antibiotics (Joukhadar et al. 2001, Roberts et al. 2009b). As β-lactams are 
predominantly renally eliminated, decrease in renal function occurring in septic 
patients with AKI leads to reduced drug clearance, while extracorporeal 
clearance is highly dependent on the method and dose of renal replacement 
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therapy applied (Jamal et al. 2015b). The extent of extracorporeal clearance is 
also dependent on the protein binding of the drug. As only the free fraction can 
be eliminated by RRT, antibiotics with low or moderate protein binding are 
more affected by extracorporeal clearance (Choi et al. 2009). According to 
general belief highly protein bound antibiotics are not eliminated by RRT, yet 
decreased protein binding due to critical illness hypoalbuminaemia may result 
in their substantial extracorporeal clearance and insufficient plasma con-
centrations (Ulldemolins et al. 2011, ). 
 
2.2.1 Pharmacokinetic/pharmacodynamics target  
of β-lactam antibiotics 
Beta-lactams are time-dependent antibiotics and the PK parameter most 
correlated to the antibacterial efficacy is the time above minimal inhibitory 
concentration (T>MIC) during the dosing interval (Vogelman et al. 1988, Craig 
2003). For bactericidal effect, 35–40% of time above MIC has commonly been 
reported as sufficient for carbapenems (Drusano et al. 2003, van Wart et al. 
2009) and 40–50% of time over MIC for penicillins (Craig 1998). A recent 
prospective study of eight β-lactam antibiotics in 248 infected critically ill 
patients found, that positive clinical outcome, defined as completion of 
treatment course without change or addition of antibiotic therapy was associated 
with antibiotic exposure of more than 50%T>MIC (Roberts et al. 2014c). In 
febrile neutropenia patients with bacteraemia clinical response rate was 80%, 
when meropenem concentrations exceeded MIC for 75% of time (Ariano et al. 
2005). Maintaining carbapenem concentrations at four to six times over MIC 
throughout the dosing interval has been shown to ensure better cell kill and 
resistance suppression in in vitro and in vivo experiments with different isogenic 
strains of Pseudomonas aeruginosa (Tam et al. 2005, Louie et al. 2010, Soon et 
al. 2013). Some analyses of clinical data have reached similar results (Tam et al. 
2002, Li et al. 2007, Taccone et al. 2012), and some recent PK/PD studies in 
critically ill patients undergoing RRT have used the target of 100%T>4xMIC 
(Jamal et al. 2015a, Jamal et al. 2015c) 
In summary, treating infections in critically ill patients with β-lactam 
antibiotics at least 50%T>MIC should be targeted. 
 
2.2.2 Pharmacokinetics of doripenem  
during renal replacement therapy 
Doripenem is a carbapenem antibiotic with molecular mass of about 420 Da, 
hydrophilic properties and protein binding of 8%. (European Medicines Agency 
2014).  
During RRT, the PK of doripenem has mostly been studied in patients on 
continuous renal replacement therapies (Table 2). Cirillo and colleagues (Cirillo 
et al. 2011) performed a single dose PK study in end-stage renal failure patients 
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on continuous veno-venous haemofiltration (CVVH) with substitution fluid flow 
rate of 2 L/h, and on continuous veno-venous haemodiafiltration (CVVHDF) 
with dialysate and substitution fluid flow rate of 1 L/h each, and found that 38% 
and 29% of the administered doripenem dose was removed by CVVH and 
CVVHDF, respectively. Total body clearance of doripenem was 4.9 L/h and 
5.9 L/h for CVVH and CVVHDF, respectively. Based on the data from this 
study, Samtani and colleagues recommended doses of 250 mg every 12 hours 
for treating infections caused by susceptible bacteria in patients undergoing 
CVVHF and 250 mg – 500 mg every 12 hours in patients undergoing CVVHDF 
(Samtani et al. 2012). Hidaka and colleagues studied critically ill patients with 
severe renal impairment undergoing low dose CVVHDF with dialysate flow 
rate of 0.5 L/h and substitution fluid flow rate of 0.3 L/h and found doripenem 
total body clearance of 3.5 L/h (Hidaka et al. 2010). A very small study from 
the same centre showed increased total body clearance of doripenem to 7.1 L/h, 
when CVVHDF was performed with dialysate flow rate of 1.5 L/h and effluent 
rate of 0.9 L/h (Ohchi et al. 2011). Roberts and colleagues studied the PK of 
doripenem in critically ill patients undergoing CVVHDF with mean dialysate 
and prefilter substitution fluid flow rate of 1 L/h each, found total body 
clearance of doripenem of 4.5 L/h and recommended dosing of 500 mg every 
8 hours for critically ill patients to cover bacteria with MIC up to 4 mg/L 
(Roberts et al. 2014d). Wieczorek and colleagues studied the PK of doripenem 
in septic shock patients during slow low efficiency haemodialysis (SLED) with 
dialysis fluid flow rate of 125 mL/min and concluded that dosing pattern 
proposed by the manufacturer can be used in patients receiving CRRT SLED 
without necessary modifications (Wieczorek et al. 2014). Unfortunately the 
authors did not report, which dose was studied or which recommendations of 
the manufacturer regarding the type of RRT and patient’s glomerular filtration 
should be followed. 
Doripenem PK has also been studied during intermittent haemodialysis with 
dialysis fluid flow rate of 500 mL/min, and significant removal of doripenem 
with total body clearance of 7.1 L/h during dialysis has been shown (Tanoue et 
al. 2011). The authors recommended doses 500 mg every 12 hours for the first 
day, followed by 500 mg every 24 hours for treating infections caused by 
Pseudomonas aeruginosa (Tanoue et al. 2011). Another study recommended 
also 500 mg every 24 hours for treatment of Pseudomonas infections in chronic 
renal failure patients undergoing intermittent haemodialysis, based on measured 
doripenem concentrations above 2 mg/L in all time points with this dosing, no 






2.2.3 Pharmacokinetics of piperacillin during  
renal replacement therapy 
Piperacillin is an ureidopenicillin with hydrophilic properties, molecular mass 
of about 520 Da and protein binding of 30%. (Pfizer Ltd. 2013). 
Pharmacokinetics of piperacillin has been studied during intermittent as well 
as during continuous renal replacement therapies and the results of the studies 
vary a great deal (Table 2). Francke and colleagues found that approximately 
48% of the administered dose of piperacillin was recovered in dialysate within 
four hours, when intermittent haemodialysis was conducted with dialysate flow 
rate of 600 mL/min and blood flow rate of 250–300 mL/min (Francke et al. 
1979). Similar haemodialysis clearance of piperacillin was described by Heim-
Duthoy and colleagues (Heim-Duthoy et al. 1986). In contrast with these results, 
another study found that only 10% of the administered dose was removed 
during 4-hour haemodialysis session (Giron et al. 1981). Results of the early 
studies of continuous renal replacement therapies are similarly controversial. 
While Capellier and colleagues found no significant elimination of piperacillin 
with continuous veno-venous haemofiltration with mean ultrafiltrate flow rate 
of 0.8 L/h (Capellier et al. 1998), other studies have shown extracorporeal 
clearance exceeding 25% with continuous arterio-venous (Keller et al. 1995) or 
veno-venous hemofiltration (van der Werf et al. 1997, Joos et al. 1996, Arzuaga 
et al. 2005), haemodialysis (Mueller et al. 2002) and haemodiafiltration (Valtonen 
et al. 2001). These studies used conventional doses of continuous renal replace-
ment therapy with ultrafiltrate flow rates of 0.8–1.5 L/h and dialysis flow rates 
of 1–2 L/h. Piperacillin clearance was shown to be dependent on ultrafiltration 
flow rate (van der Werf et al. 1997) and dialysis flow rate (Valtonen et al. 
2001). Adding dialysis to filtration was shown to increase piperacillin clearance 
(Valtonen et al. 2001), while CVVHD was as efficient in removal of 
piperacillin as CVVHDF (Bauer et al. 2012). More recent studies have shown 
total piperacillin clearance of 3.9 L/h (Bauer et al. 2012) to 5.1 L/h (Varghese et 
al. 2014), depending on the intensity of RRT and on the patient’s residual renal 
function (Arzuaga et al. 2005, Asin-Prieto et al. 2013). A recent regression 
analysis of published PK data also found effluent rate to be the main predictor 
of piperacillin clearance in critically ill patients undergoing continuous RRT 
(Jamal et al. 2014b). The most commonly recommended dose of piperacillin for 
these patients during continuous RRT is 4 g every 8 hours (Valtonen et al. 2001, 
Asin-Prieto et al. 2013, Varghese et al. 2014), while increasing the dose to 4 g 
every 4 hours is recommended for patients with normal renal function when 
they are treated with continuous RRT (Asin-Prieto et al. 2013).  
Most studies have found significant interindividual variability in piperacillin 
concentrations (Francke et el. 1979, van der Werf et al. 1997, Giron et al. 1981, 
Mueller et al. 2002, Arzuaga et al. 2005, Seyler et al. 2011, Bauer et al. 2012, 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In summary, pharmacokinetics of doripenem and piperacillin/tazobactam has 
not been studied during HVHDF. Different methods of RRT result in different 
clearance of both antibiotics. While effluent rate seems to be the RRT parameter 
most correlated to extracorporeal clearance of β-lactams (Jamal et al. 2014b), 
systemic clearance of these antibiotics may not be consistently RRT dose 
dependent (Roberts DM et al. 2015). No dosing recommendations for HVHDF 
can be derived from the existing PK data. 
 
2.2.4 Pharmacokinetics of tazobactam during renal 
replacement therapy 
Tazobactam is a β-lactamase inhibitor, added to β-lactam antibiotics to extend 
their spectrum of activity and retain the activity of the β-lactam antibiotic 
despite the effect of hydrolysing β-lactamase enzymes, although β-lactamase 
inhibitors have little antibiotic activity of their own (Harris et al. 2015). It is a 
hydrophilic molecule with molecular mass of about 300 Da. (European 
Chemical Agency 2014). In healthy volunteers the PK of tazobactam is similar 
to piperacillin with similar terminal elimination half-life, protein binding, volume 
of distribution and predominantly renal elimination (Occhipinti et al. 1997).  
During continuous renal replacement therapy total body clearance of tazo-
bactam from 2.4 L/h (CVVHF, Valtonen et al. 2001) to 3.8 L/h (CVVHDF, 
effluent rates of 3–3.9 L/h, Varghese et al. 2014) has been described. Some 
studies (van der Werf et al. 1997, Mueller et al. 2002, Asin-Prieto et al. 2013) 
have shown relative accumulation of tazobactam and suggested increasing 
piperacillin dose relative to that of tazobactam to avoid tazobactam cumulation.  
 
2.2.5 Administration via bolus or extended infusion 
Several studies and modelling of PK data of β-lactam antibiotics show better 
PK/PD target achievement in critically ill patients when given as extended or 
continuous antibiotic infusion instead of intermittent bolus (Li et al. 2005, 
Bhavnani et al. 2005, Langgartner et al. 2007, Roberts et al. 2009a, Roberts et 
al. 2010a, Samtani et al. 2012, Felton et al. 2012, Dulhunty et al. 2013, Asin-
Prieto et al. 2014, De Waele et al. 2014). Jamal et al. compared continuous and 
intermittent bolus administration of piperacillin/tazobactam in critically ill 
patients undergoing continuous haemofiltration and found better PK/PD target 
attainment with continuous infusion (Jamal et al. 2015c). A study of mero-
penem in similar settings did not find any differences in PK/PD target 
attainment (Jamal et al. 2015a). Meropenem doses used were as recommended 
for normal renal function, while piperacillin/tazobactam was used in reduced 
doses (Jamal et al. 2015a, Jamal et al. 2015c). In both studies both groups 
received a bolus loading dose. Meropenem doses used were the recommended 
doses for normal renal function, while piperacillin/tazobactam was used in 
reduced doses (Jamal et al. 2015a, Jamal et al. 2015c). In terms of mortality 
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and/or clinical cure the evidence of benefit from extended or continuous 
infusion of β-lactam antibiotics is less convincing (Lorente et al. 2009, Hsaiky 
et al. 2013, Lodise et al. 2007). Some randomized controlled trials have showed 
equivalence of continuous β-lactam infusion compared to bolus administration 
(Lau et al. 2006, Georges et al. 2005, Hanes et al. 2000, Nicolau et al. 2001). In 
a randomised open-label study continuous infusion of ceftriaxone suggested 
clinical and bacteriological benefit (Roberts et al. 2007). A multicentre double-
blind randomized controlled trial comparing intermittent dosing of piperacillin/ 
tazobactam, meropenem and ticarcillin/clavulanate to continuous administration 
found better clinical cure in the continuous administration group (Dulhunty et 
al. 2013a). There was no difference in ICU-free days or mortality, but the study 
was not powered to evaluate effect on survival (Dulhunty et al. 2013a). Two 
meta-analyses of mostly non-randomised studies found clinical benefit or lower 
mortality for extended or continuous infusion of β-lactam antibiotics (Falagas et 
al. 2013, Teo et al. 2014). In the meta-analysis by Falagas and colleagues, the 
effect on mortality was present in carbapenems and piperacillin/tazobactam 
analysed together and piperacillin/tazobactam alone, but not for carbapenems 
alone (Falagas et al. 2013). A Cochrane database systematic review on the other 
hand concluded that continuous infusion of antibiotics has no benefit over 
standard intermittent infusion in terms of mortality, infection recurrence, clinical 
cure, super-infection or safety (Shiu et al. 2013). A recent meta-analysis, 
comparing extended and continuous infusion of piperacillin/ tazobactam to 
intermittent bolus administration and including 5 randomised controlled trials 
and 9 observational studies, found higher clinical cure rate and lower mortality 
rate with extended or continuous infusion (Yang et al. 2015). A very recent 
large randomized controlled trial comparing the effect of intermittent vs 
continuous administration of three β-lactam antibiotics (ticarcillin/clavulanate, 
piperacillin/tazobactam and meropenem) in 432 patients with severe sepsis 
found no difference in ICU-free days at day 28 as the primary outcome 
(Dulhunty et al. 2015).  
 
 
 2.3 Summary of literature 
High volume haemodiafiltration as an extracorporeal blood purification method 
might be useful in the treatment of patients with refractory septic shock in order 
to control excessive immunological reaction and achieve haemodynamic stabili-
sation, when conventional methods fail. As removal of antibiotics is dependent 
of the dose and method of RRT, potentially excessive removal of antibiotics 
during HVHDF may lead to low plasma concentrations, ineffective antibacterial 
therapy, worse clinical outcome and potential escalation of antibiotic resistance. 
On the other hand, increasing doses of antibiotics empirically may lead to 
toxicity. No pharmacokinetic data of β-lactam antibiotics during HVHDF are 
available and no dosing recommendations for HVHDF can be derived from the 
existing PK data. 
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3. AIMS OF THE STUDY 
The general aim of the thesis was to describe the influence of high volume 
haemodiafiltration on the pharmacokinetics of two beta-lactam antibiotics and 
systemic inflammatory reaction in patients with severe sepsis and septic shock. 
We hypothesized that HVHDF markedly changes the pharmacokinetic profile 
of doripenem and piperacillin/tazobactam, and is associated with beneficial 
modifications of whole body inflammatory response in patients with severe 
sepsis and septic shock  
 
The specific aims were as follows: 
1. To describe the pharmacokinetics of doripenem during HVHDF in patients 
with severe sepsis and septic shock with acute kidney injury in order to 
define optimal dosing for this method of RRT in this patient group. 
2. To describe the pharmacokinetics of piperacillin and tazobactam during 
HVHDF in patients with severe sepsis and septic shock with acute kidney 
injury in order to define optimal dosing for this method of RRT in this 
patient group. 
3. To find out if HVHDF influences cytokines profile and/or has effect upon 
central haemodynamics or sublingual microcirculation in critically ill severe 
sepsis and septic shock patients. 
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4. PATIENTS AND METHODS 
The thesis is based on a clinical study with three substudies conducted in the 
general intensive care unit (ICU) of Tartu University Hospital from September 
1, 2011 till June 25, 2014 (Table 3) 
 
 
4.1 Ethical considerations 
The study was approved by the Research Ethics Committee of the University of 
Tartu and by State Agency of Medicines of Estonia (EU Clinical Trials Register 
No. 2011-000644-16). Informed consent from next of kin was obtained for all 
patients prior to study inclusion. The patient’s informed consent was obtained 
retrospectively, if he/she recovered sufficiently. 
The blood loss from blood sampling was not clinically significant as the 
blood volume removed was 60 mL, which is no more than 1.5% of the presumed 
circulating blood volume. 
 
4.2 Study patients 
Adult patients were eligible for the study, if they had severe sepsis or septic 
shock as defined by the ACCP/SCC Consensus Conference as follows: 
(1) severe sepsis: systemic response to infection manifested by two or more of 
the following conditions as a result of infection: temperature >38°C or <36°C, 
Table 3. Description of studies and analyses of the thesis. 
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heart rate >90 beats per minute, respiratory rate >20 breaths per minute or 
PaCO<32 mm Hg, leucocytosis or leucopenia, and signs of organ dysfunction, 
hypoperfusion or hypotension; (2) septic shock: sepsis-induced hypotension 
despite adequate fluid resuscitation along with the presence of perfusion 
abnormalities (Bone et al. 1992). The patients had to have acute kidney injury 
(AKI) deemed by the treating clinician to require HVHDF, based on the 
presence of at least one of the following criteria: (1) oliguria (urine output 
<100 ml in a 6-hour period), unresponsive to fluid therapy, (2) serum potassium 
concentration exceeding 6.5 mEq/L, (3) severe acidemia (pH <7.2), (4) plasma 
urea nitrogen level above 70 mg/dL, (5) serum creatinine concentration above 
3.4 mg/dL, or (6) presence of clinically significant organ oedema (e.g., pulmo-
nary oedema), and an arterial line in situ. Patients with known hypersensitivity 
to carbapenems, penicillins or other beta-lactams, pregnancy, and life expec-
tancy of less than 8 hours were excluded. 
 
 
4.3 High volume haemodiafiltration 
Extended HVHDF in the ultracontrol predilution mode with AK 200 ULTRA S 
(Gambro, Lund, Sweden) as described by Kron et al (Kron 2011) was applied. 
At the beginning of treatment this mode titrates filtration volume to the 
maximal possible by gradually increasing transmembrane pressure by 25 mmHg 
every 30 seconds until maximal filtration rate is achieved. Subsequently, this 
pressure is maintained at maximum effectiveness by testing and adjusting once 
every hour. HVHDF was performed with capillary dialyzer Polyflux 210H 
(Gambro Dialysatoren, Hechingen, Germany) with surface area 2.1 m2 and ultra-
filtration coefficient 85 ml/h/mmHg. The procedure was performed via 3-lumen 
central venous catheter with blood flow rate of 200 mL/min and fluid flow rate 
of 500–650 mL/min. The substitution fluid is taken from the dialysis fluid thus 
reducing the dialysis fluid flow rate. The prescribed duration of the HVHDF 
was 10 hours. 
 
4.4 Patient monitoring 
All patients were treated in third level intensive care unit and thus thoroughly 
monitored on clinical grounds. Clinical blood tests (red blood cells, white blood 
cells, haemoglobin, haematocrit and platelet count), serum biochemistry, 
arterial blood gases and lactate were monitored according to clinical routine of 
the ICU. Serum electrolytes (sodium, calcium, and phosphate), creatinine and 
urea were measured before the HVHDF procedure, and within 24 hours after it. 
Serum potassium, glucose and activated partial thromboplastin time (APTT) 
were monitored every four hours during the HVHDF procedure. Body tem-
perature was continuously monitored during the haemodiafiltration procedure 
and external warming applied, if necessary. 
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All patients were monitored for adverse events for at least 7 days after study 
drug administration. Monitoring included clinical evaluation for occurrence of 
allergic reactions and seizures, laboratory and vital parameters and micro-




 4.5 Substudy I. Pharmacokinetics of doripenem 
during high volume haemodiafiltration 
4.5.1 Study drug administration and sample collection 
A single dose of 500 mg of doripenem (Doribax, Janssen-Cilag International 
N.V) in 50 mL of 0.9% sodium chloride was administered in addition to the 
ongoing antibacterial therapy as a 1 hour intravenous infusion. The dose was 
administered one hour after the start of HVHDF via a central venous cannula, 
which was not used for hemodiafiltration. 
Blood samples of 4 mL were collected before and immediately after the end 
of doripenem infusion and 90, 120, 150, 180, 210, 240, 300, 360, 420 and 
480 min after the start of drug administration. Blood samples were drawn to 
lithium heparin containing tubes from pre-existing arterial cannula. Blood 
samples were centrifuged immediately (10 min at 3500 rpm), plasma was sepa-
rated, stored at –20oC for a maximum of 12 hours and then transferred to –80ºC 
until analysed within 12 months.  
Doripenem plasma concentrations were measured with ultrahigh perfor-
mance liquid chromatography-double mass spectrometry as detailed in paper I 
(pp. 439 – 440). 
 
4.5.2 Non-compartmental pharmacokinetic analysis 
Based on the observed plasma levels of total concentrations, the half-life (T1/2) 
and the elimination rate constant (Kel) of doripenem during HVHDF were 
derived using noncompartmental analysis. Plasma concentrations and PK 
parameters of doripenem during HVHDF were summarized using descriptive 
statistics. All calculations were performed using the WinNonlin Phoenix 
version 6.5.1 (Pharsight Corporation, CA). 
 
4.5.3 Population pharmacokinetic analysis 
PK data were analysed by non-linear mixed effect modelling (NLME) using 
NONMEM 7.3.0 by Joseph Standing (University College of London). One-, 
two- and three-compartment linear models were tested. Inter-individual 
variability was described using an exponential error model and residual 
unexplained variability with a proportional error model. The selection of the 
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population model and residual error model was driven by goodness-of fit plots 
and an improvement in the objective function value (OFV). The potential effect 
of covariates on PK parameters was evaluated if a correlation was biologically 
plausible or by the visual inspection of box and scatter plots of individual 
estimates derived from the final model and inter-individual variability (ETAs) 
compared against covariates. Covariates that reduced the OFV by at least 6.635 
points (p<0.01) were considered statistically significant and included in the 
subsequent covariate analysis. 
 
4.5.4 Pharmacodynamic target attainment 
The parameter estimates of the final PK model were used as inputs within 1000 
Monte Carlo simulations to assess the PD target attainment ability of doripenem 
on HVHDF. Fraction of time over minimal inhibitory concentration (fT>MIC) 
for 50% of dosing interval was selected as PD target (Roberts et al. 2014c). 
Mean serum protein binding of doripenem is around 8% (European Medicines 
Agency) and this was accounted for in simulations. 
Since in vitro data have shown that Gram negative resistance to doripenem 
can develop over the first 48 hours of treatment (Bowker et al. 2012), the target 
MIC was allowed to double over this period using a linear model. Continuous 
HVHDF was assumed and the probability of target attainment (PTA) after the 
first dose and at 48 hours was calculated for dosing regimens of 500mg and 
1000 mg every 6, 8, 12 and 24 hours for the European Committee of Anti-
microbial Susceptibility Testing (European Committee on Antimicrobial 
Susceptibility Testing 2014) defined MIC susceptibility and resistance break-
points of doripenem for Enterobacteriaceae and Pseudomonas of ≤1 and 
>2 μg/mL. In 2013, when the analysis was conducted, the EUCAST resistance 
breakpoint for both Pseudomonas and Enterobacteriaceae was <4 mg/L 
(European Committee on Antimicrobial Susceptibility Testing 2013), so the 
simulations were conducted also for MIC of 4 μg/mL.  
 
 
4.6 Substudy II. Pharmacokinetics of piperacillin/ 
tazobactam during high volume haemodiafiltration 
4.6.1 Study drug administration and sample collection 
A single dose of 4000 mg of piperacillin and 500 mg of tazobactam in fixed 
commercially available combination in 50 mL of 0.9% sodium chloride was 
administered in addition to the ongoing antibacterial therapy as a 30 minute 
intravenous infusion. The dose was administered one hour after the start of 
HVHDF via a central venous cannula, different from that used for haemo-
diafiltration. 
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Blood samples of 4 mL were collected before and immediately after the end 
of piperacillin/tazobactam infusion and 60, 90, 120, 150, 180, 240, 300, 360, 
420 and 480 min after the start of drug administration. In two patients samples 
were also collected 12 h and 24 h after the study drug administration, when the 
patients were off RRT. Blood samples were drawn to lithium heparin containing 
tubes from arterial cannula. Blood samples were centrifuged immediately 
(10 min at 3500 rpm), plasma was separated, stored at –20°C for a maximum of 
12 hours and then transferred to –80°C until analysed within 12 months. 
Piperacillin and tazobactam plasma concentrations were measured with 
ultrahigh performance liquid chromatography-double mass spectrometry as 
detailed in paper II (pp. 5–7). 
 
4.6.2 Non-compartmental pharmacokinetic analysis 
Based on the observed plasma levels of total concentrations, the half-life (T1/2) 
and the elimination rate constant (Kel) of piperacillin and tazobactam during 
HVHDF were derived using noncompartmental analysis. Plasma concentrations 
and PK parameters of piperacillin and tazobactam during HVHDF were 
summarized using descriptive statistics. All calculations were performed using 
the WinNonlin Phoenix version 6.5.1 (Pharsight Corporation, CA). 
 
4.6.3 Population pharmacokinetic analysis 
Piperacillin and tazobactam were modelled separately by Tõnis Tasa (Faculty of 
Mathematics and Computer Science, University of Tartu). Plasma concen-
trations observed during HVHDF were fitted to a 1- and 2-compartment model 
with zero-order input and first-order elimination. Non-linear mixed effects 
modelling approach was used and model training was based on iterative 
improvements of log-likelihood values. Model discrimination was accom-
plished by visual inspection of the predicted versus observed concentration data, 
visual inspection of the distribution of the standardized residuals over fitted 
values and over time, log-likelihood values, Akaike information criteria and 
sums of the squared weighted residuals. Visual predictive checks were created 
by evaluation of 1000 concentration-time profiles for each of the two models. 
From these the median concentration profile with 90% confidence intervals 
were deduced and overlaid on the observed concentration measurements. 
Random effects without an underlying covariance structure of diagonal 
structure were modelled for all fixed effects and log-normal distribution was 
assumed.  
For piperacillin, residual variability was modelled using a combined additive 
power variance structure where variance equals to a constant plus power of the 
variance covariate where the residuals are distributed as N~(0,σ2*(δ1+|η|δ2)2 ) 
where η is the fitted value covariate, σ is standard deviation of the residuals, δ1 
is the constant parameter and δ2 the power parameter. 
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For tazobactam, residual variability was modelled using an exponential 
model where the residuals follow normal distribution of the form N(0,  
σ 2*exp(2*δ*η), where η is the fitted value covariate, σ is standard deviation of 
the residuals and δ is the exponential parameter. 
 
4.6.4 Pharmacodynamic target attainment 
The final piperacillin population PK model was used in a 1000-patient Monte 
Carlo simulation (MCS) to generate concentration-time profiles for various 
dosing regimens and lengths of infusions during HVHDF at steady-state. The 
free drug time over minimal inhibitory concentration (fT>MIC) at steady state 
was calculated for piperacillin 4g administered every 6 and 8 hours as 0.5h and 
4h infusion. The EUCAST defined susceptibility and resistance breakpoint 
MIC-s of ≤8 and >16 mg/L for Enterobacteriaceae, ≤16 and >16 mg/L for 
Pseudomonas (EUCAST 2015) and serum protein binding of 30% (Roberts et 
al. 2009a) for piperacillin were used in the calculations. For all dosing regimens 
probabilities of target attainment were found for targets of 50% and 100% of 
fT>MIC with bootstrapped 90% confidence intervals. 
The final tazobactam model was used in 1000-patient MCS to simulate con-
centration-time profiles during HVHDF for dosing regimens of 500 mg as 0.5h 
infusion every 6 and 8 hours. Population PK analysis and MCS were performed 
using base R (version 2.15.2 (2012-10-26), The R Foundation for Statistical 
Computing) and package “nlme” (Pinheiro et al. 2014). 
 
 
 4.7 Substudy III. Modification of inflammatory 
response by high volume haemodiafiltration  
in patients with severe sepsis and septic shock 
4.7.1 Blood sample collection and handling 
Blood samples were taken from a pre-existing arterial cannula immediately 
before the start and after the end of HVHDF session in the study, immediately 
centrifuged and stored at –20oC for a maximum of 12 hours and then transferred 
to –80ºC until analysed. 
The following cytokines and growth factors: IL-1, IL-2, IL-6, IL-8, TNF-α, 
IF-γ, MCP-1, IL-4, IL-10, EGF and VEGF were measured in sera with the 
Evidence Investigator Cytokine & Growth factors high-sensitivity array (CTK 
HS Cat. No. EV 3623; RANDOX Laboratories Ltd. Crumlin, UK) according to 
the manufacturer’s protocol in the Institute of Biochemistry of the University of 
Tartu. Assay sensitivity varied from 0.12 pg/L to 2.12 pg/L depending on 
specific marker analyte. The reproducibility of the assay for individual cytokine 




Sublingual microcirculation was assessed before and after HVHDF by a side-
stream dark-field (SDF) imaging device (Microscan; Microvision Medical, 
Amsterdam, The Netherlands). In total, at least nine videos were taken at each 
time point, of which five best were analysed by two observers. 
Microcirculatory videos of all patients were collected and thereafter analysed 
with the aid of specialized software (Automated Vascular Analysis 3.02; 
Academic Medical Centre, University of Amsterdam, The Netherlands) by 2 
separate investigators unaware of the study protocol.  
 
4.7.3 Statistical analysis 
All except interobserver variability calculations were performed using the 
Statistical Package for the Social Sciences (IBM SPSS Statistics 20.0, Somers, 
NY, USA) software. Normal distribution of data was confirmed by visual inspec-
tion of result histograms. Data with normal distribution are presented as mean 
(SD – standard deviation) and data not normally distributed as median (IQR – 
interquartile range). Paired t-test for normally distributed data, and Wilcoxon 
matched pairs test for not normally distributed data were used to compare 
prediafiltration values against postdiafiltration values. Differences were 
considered significant at p < 0.05. 
Interobserver variability was calculated separately for each parameter through 
the Bland-Altman analysis for assessing agreement between two opinions 





 5.1 Patients 
Of 36 screened patients, 19 were enrolled in the study: nine in substudy I and 10 
in substudy II, while all the patients participated in substudy III. The reasons for 
exclusion were absence of informed consent from next of kin (11 patients), life 
expectancy of < 8 hours (5 patients), and age <18 years (1 patient). The 
demographics and clinical characteristics of the patients at baseline are shown 
in Table 4. Eighteen patients were mechanically ventilated and all except one 
received norepinephrine at the start of HVHDF. In addition six patients received 
dopamine, dobutamine or milrinone. Bedside nurses maintained the mean 
arterial pressure (MAP) at the target range, defined by the treating physician 
(70–80 mmHg) by adjusting the dose of norepinephrine infusion. The focus of 
infection was pneumonia in 6 cases, intraabdominal (peritonitis, cholangitis, 
infected pancreatic necrosis) in 10 cases and soft tissue in 3 cases. The median 
(range) time from ICU admission to the study inclusion was 45 (6–361) hours. 
Seventeen patients had received renal replacement therapy before the studied 
HVHDF. The median (IQR) fluid balance during the studied HVHDF was –409 
(–1405–25.75) mL. Sixteen patients were discharged from ICU alive, three died 
in the ICU: one within 48 hours after study inclusion due to refractory septic 
shock and two more than two weeks later due to multiple organ failure. The 
median (IQR) ICU stay of the patients was 23 (9–44) days. 
The patient’s estimated glomerular filtration rate (eGFR) was calculated 





Table 4. Demographic and clinical characteristics of study patients at baseline.  
 Median (IQR) 
Age (years) 65 (56–72) 
Gender (male/female) 12/7 
Weight (kg) 80 (70–100) 
APACHE II 19 (16–20) 
SOFA 10 (7–11) 
C-reactive protein (mg/L) 252 (121–316) 
Creatinine before inclusion (μmol/L) 164 (127–348) 
eGFR (mL/min/1.75m2) 18 (11–28.5) 
Lactate before inclusion (mmol/L) 1.5 (1.2 – 3.0) 
ICU cumulative fluid balance (mL) 3328 (–702–5381) 
APACHE II – Acute Physiology and Chronic Health Evaluation score II, eGFR – estimated 
glomerular filtration rate, ICU – intensive care unit, SOFA – Sequential Organ Failure Score 
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 5.2 High volume haemodiafiltration 
The studied HVHDF was performed for 10 hours in 17 patients. In two patients 
of the piperacillin/tazobactam substudy group the HVHDF was terminated after 
4 hours due to filter clotting. One patient in the doripenem substudy group had a 
1-hour and one patient in the piperacillin/tazobactam substudy group had a  
2-hour break in HVHDF due to filter clotting. The mean (SD) time of HVHDF 
was 9.4 (1.8) hours. The median convective volume was 11.5 L/h (IQR 8.8 – 
15.9) [123 mL/kg/h (IQR 100–211 mL/kg/h)]. Anticoagulation was performed 
with unfractionated heparin or heparin/protamine as clinically indicated. 
 
 
5.3 Adverse events 
One patient developed atrial fibrillation during the HVHDF and one developed 
severe hypotension at the beginning of the procedure, stabilized with infusion 
therapy and temporary increase in norepinephrine dose. No other adverse events 
including hypothermia, severe hypophosphataemia or hypokalaemia were 
observed. 
No adverse events or changes in laboratory parameters were documented 
after doripenem or piperacillin/tazobactam administration (Table 5). 
 





 Pre HVHDF Post HVHDF p 
Hb (g/L) 101 (91–120) 104 (90–110) NS 
Hct 0.31 (0.27–0.38) 0.31 (0.27–0.33) NS 
WBC *109/L 11.4 (6.1–19.7) 12.3 (5.9–21.0) NS 
CRP 252 (121–316) 246 (119–313) NS 
Bilirubin 22.5 (14.5–47.75) 19.5 (12.0–42.25) NS 
ALT 29 (19–135) 29 (18–152) NS 
AST 42 (21–68) 39 (24–233) NS 
Albumin 28 (25.5–32.5) 27 (26–34) NS 
ALT – alanine aminotranferase, APAHE II – acute physiology and chronic health evaluation II 
score, AST – aspartate aminotransferase, CRP – C-reactive protein, Hb – haemoglobin, Hct – 





 5.4 Substudy I. Pharmacokinetics of doripenem 
during high volume haemodiafiltration 
5.4.1 Non-compartmental PK analysis 
Nine subjects were included in the PK analysis. Doripenem concentrations were 
measurable 480 min post dose and exceeded the EUCAST susceptibility criteria 
MIC value of 1 mg/L for 8/9 subjects. Doripenem concentrations demonstrated 
high variability after a single 500 mg 1 hour infusion (Figure 2). 
 
 




The PK parameters of doripenem in the study patients are shown in Table 6. 
 
Table 6. Noncompartmental PK parameters of doripenem during HVHDF. 
Patient Cmax 
(mg/L) 
Kel (/h) T1/2 
(h) 






ID-1 20.9 0.340 2.0 29.2 46.9 50.6 10.6 
ID-2 27.2 0.398 1.7 22.9 48.2 51.0 10.3 
ID-3 18.9 0.375 1.8 31.0 38.6 40.6 12.9 
ID-4 12.4 0.258 2.7 54.6 32.9 38.0 15.0 
ID-5 30.7 0.286 2.4 23.7 70.1 79.0 7.1 
ID-6 26.2 0.263 2.6 25.3 75.0 87.9 6.6 
ID-7 34.1 0.262 2.6 23.8 74.0 86.7 6.7 
ID-8 23.7 0.212 3.3 30.5 83.8 110.7 5.9 

















AUCinf – area under the time-concentration curve extrapolated to infinity; AUCτ – area under the 
time-concentration curve during the dosing interval; CL – total body clearance; Cmax – maximal 
concentration; Kel – elimination rate constant; T1/2 – terminal elimination half life ; Vd – volume of 
distribution 
 
5.4.2 Population PK analysis 
A 2-compartment model fitted the concentration–time data best. Goodness of fit 
plots and visual predictive check of the final model are shown in Figures 3 and 
4. Inclusion of the tested covariates (serum creatinine, APACHE II, effluent 
rate, effluent volume and fluid removal volume) did not significantly improve 
the model fit and they were not retained in the final model. The PK parameter 




Figure 3. Goodness of fit plots from the final doripenem population PK model. A: 
Population predictions versus observations; B: Individual predictions versus observa-
tions; C: Conditional weighted residuals versus time; D: Individual plots with ob-
servations as open circles, population predictions as blue dashed line, individual 





Figure 4. Visual predictive check of the final doripenem population model. The dashed 
bottom line marks the 5th percentile, the solid middle line marks the 50th percentile and 
the top dashed line marks the 95th percentile of model predicted data. The open circles 
represent the observed data, shaded areas are the corresponding 95% confidence 
intervals of model-simulated percentiles. 
 
 
Table 7. Parameter estimates of the final doripenem population PK model. 
Parameter Estimate IIV RSE Bootstrap CI 
CL (L/h) 6.82 33% 12% 6.80 6.95 7.19 
V1 (L) 10.8 0% 7.6% 10.54 10.68 10.82 
Q (L/h) 8.75 79% 30% 8.29 9.17 10.04 
V2 (L) 12.1 25% 11% 12.01 12.8 13.64 
CI – 95% confidence interval; CL– total doripenem clearance; IIV – inter-individual 
variability; Q – intercompartmental clearance; RSE – residual standard error; V1 –





5.4.3 Probability of target attainment 
Figures 5 and 6 demonstrate the spread of the fT>MIC for the 1000 simulated 
patients for the tested dosing regimens after the first dose and 48 hours. The 
median probability of target attainment at 48 hours for 500 mg dosed every 6, 8, 
12 and 24 hours were 99.9%, 98.8%, 85.7% and 19.9% respectively for an 
initial MIC of 1 μg/mL. For 1000 mg doripenem doses the median PTA values 
for initial MIC of 4 μg/mL at 48 hours were 97.2%, 88.5%, 49.8% and 1.8% 




Figure 5. Box and whisker plots for fT>MIC of 1 μg/mL (left), 2 μg/mL (middle) and 
4 μg/mL (right) for different dosing frequencies of 500 mg of doripenem after 1 dose 
and after 48 hours. These figures assume MIC doubles over the first 48 hours of 
treatment. Probability of target attainment given at the bottom of each plot with the 
target set at fT>MIC of 50%. The bottom and top of the box represent first and third 
quartile, respectively, the line inside the box represents median, the whiskers represent 
the box quartile +/– the interquartile range and the open circles represent outliers. 
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Figure 6. Box and whisker plots for fT>MIC of 1 μg/mL (left), 2 μg/mL (middle) and 
4 μg/mL (right) for different dosing frequencies of 1 g of doripenem after 1 dose and 
after 48 hours. These figures assume MIC doubles over the first 48 hours of treatment. 
Probability of target attainment given at the bottom of each plot with the target set at 
fT>MIC of 50%. The bottom and top of the box represent the first and third quartile, 
respectively, the line inside the box represents median, the whiskers represent the box 




5.5 Substudy II. Pharmacokinetics  
of piperacillin/tazobactam  
during high volume haemodiafiltration 
5.5.1 Non-compartmental PK analysis  
Ten subjects were included in the PK analysis. The plasma concentration time 
profiles of piperacillin and especially tazobactam demonstrated high inter-
individual variability (Figure 7). No increase of serum concentrations after the 




The PK parameters of piperacillin and tazobactam in the study patients are shown 





Figure 7. Plasma concentration – time profiles of (a) piperacillin and (b) tazobactam. 
The open circles, squares and triangles mark measured concentrations off HVHDF 































































ID-1 299.7 0.291 2.4 19.1 638.9 703.3 6.3 
ID-2 317.0 0.328 2.1 19.6 525.0 561.6 7.6 
ID-3 356.4 0.484 1.4 13.5 571.4 585.0 7.0 
ID-4 258.4 0.241 2.9 32.3 482.8 577.6 8.3 
ID-5 219.9 0.365 1.9 23.0 411.2 430.4 9.7 
ID-6 338.2 0.328 2.1 21.2 621.8 691.9 6.4 
ID-7 197.8 0.384 1.8 30.7 417.3 454.1 9.6 
ID-8 323.7 0.386 1.8 19.7 428.3 447.9 9.3 
ID-9 206.1 0.287 2.4 29.3 402.0 441.3 9.9 

















AUCinf – area under the time-concentration curve extrapolated to infinity; AUCτ – area under the 
time-concentration curve during the dosing interval; CL – total body clearance; Cmax – maximal 




Table 9. Noncompartmental PK parameters of tazobactam during HVHDF. 
Patient Cmax 
(mg/L) 
Kel (/h) T1/2 
(h) 






ID-1 39.7 0.248 2.8 18.5 62.6 119.3 4.9 
ID-2 34.4 0.333 2.1 21.3 64.9 69.8 7.7 
ID-3 63.9 0.447 1.6 9.3 68.0 120.6 4.3 
ID-4 44.1 0.212 3.3 24.0 94.7 118.7 5.3 
ID-5 34.4 0.376 1.8 17.5 72.0 75.7 6.9 
ID-6 45.3 0.183 3.8 25.5 89.9 113.9 5.6 
ID-7 31.9 0.199 3.5 30.0 76.7 95.5 6.5 
ID-8 51.5 0.370 1.9 14.8 77.4 81.1 6.5 
ID-9 22.6 0.325 2.1 30.1 48.1 52.4 10.4 

















AUCinf – area under the time-concentration curve extrapolated to infinity; AUCτ – area under the 
time-concentration curve during the dosing interval; CL – total body clearance; Cmax – maximal 




5.5.2 Population PK analysis 
A 2-compartment model best fitted both the piperacillin and tazobactam on 
HVHDF concentration–time data (101 samples from 10 patients). Goodness of 
fit plots and visual predictive check of the final model are shown in Figures 8 
and 9. Inclusion of the tested covariates (serum creatinine, APACHE II, effluent 
rate, effluent volume and fluid removal volume) did not significantly improve 
the model fit and they were not retained in the final model. 
The PK parameter estimates of the final piperacillin and tazobactam PK 
models are shown in Table 10. 
 
 























































Figure 8. Goodness of fit plots from the final (a) piperacillin and (b) tazobactam 








Figure 9. Visual predictive check of the final (a) piperacillin and (b) tazobactam 
population model. The solid middle line marks the median, the dark grey shaded area 
marks the interquartile range and the light grey shaded area marks the 95% confidence 
interval of model predicted data. The red circles represent the observed data 
 
Table 10. The PK parameter estimates of the final PK model 
Piperacillin Tazobactam 
Parameter Estimate 95% CI 
Lower     Upper
Estimate 95% CI 
Lower    Upper 
Fixed effects, population mean PK parameters
CL L/h (%SE) 6.9 (6.4) 6.1 7.9 5.1 (11.0) 4.1 6.3 
V1 L (%SE) 9.0 (10.1) 7.4 11.0 8.6 (11.0) 6.9 10.7 
V2 L (%SE) 11.2 (12.2) 8.9 14.2 8.9 (15.2) 6.6 12.0 
Q L/h (%SE) 10.5 (14.4) 7.9 14.0 9.7 (19.5) 6.6 14.2 
Random effects, interindividual variability
ηCL 0.19 0.11 0.33 0.33 0.20 0.55 
ηV1 0.26 0.14 0.48 0.31 0.18 0.53 
ηV2 0.34 0.19 0.60 0.45 0.27 0.75 
ηQ 0.37 0.20 0.70 0.57 0.34 0.93 
Residual variability, constant plus power of the 
variance covariate model  
Residual variability, expo-
nential variance function 
Constant (fixed) 1 – – – – – 
Residual (SD) 0.06 0.03 0.12 0.17 0.14 0.20 
Power parameter  1.07 0.86 1.29 – – – 
Exponential (fixed) – – – 0.07 – – 
CL – total body clearance; Q – intercompartmental clearance; V1 – volume of distribution of the 
central compartment; V2 – volume of distribution of the peripheral compartment; η – fitted value 


































5.5.3 Probability of target attainment 
Figure 10 demonstrates the spread of the fT>MIC for each simulated patient for 
the tested dosing regimens. The probability of the 100%T>MIC target attain-
ment for piperacillin/tazobactam 4.5 g dosed every 6 and 8 hours as 4-hour 
infusion were 88.6%, and 61.0% respectively for MIC 16 mg/L.  
The median, 10th and 90th percentiles of simulated concentration profiles of 




Figure 10. Box and whisker plots for fT>MIC of 8 mg/L (upper) and 16 mg/L (lower) 
for different dosing frequencies and infusion durations of 4.5 g of piperacillin/ 
tazobactam. The bottom and top of the box represent first and third quartile, respec-
tively, the line inside the box represents median, the whiskers represent the box quartile 
+/– the interquartile range and the black circles represent outliers. Probability of target 
















































Figure 11. Simulated steady state concentrations of tazobactam 0.5 g administered (a) 
every 6 hours and (b) every 8 hours. The green line represents median, the red line 
represents the 10th and the blue line represents the 90th percentile 
 
 
5.6 Substudy III. Modification of inflammatory 
response by high volume haemodiafiltration  
in patients with severe sepsis and septic shock 
5.6.1 Metabolic and haemodynamic indices 
The changes in haemodynamic and metabolic parameters are shown in Table 11. 
The dose of norepinephrine required to maintain MAP within the target range of 
70–80 mmHg decreased from 0.40 (0.43) μg/kg/min to 0.28 (0.33) μg/kg/min 
during HVHDF (p=0.009). There were no statistically significant changes in 
heart rate, MAP, CI, body temperature or serum lactate concentrations. Serum 
































Table 11. Effects of HVHDF on haemodynamic and clinical variables. 
 Pre-HVHDF Post-HVHDF p 
Mean arterial pressure(mmHg) 89 [71–91] 80 [73–93] NS 
Cardiac index (L/min/m2) 3.02 [2.5–4.2] 2.9 [2.5–3.3] NS 
Heart rate (beats/min) 102.4 (26.8) 98.5 (22.9) NS 
Body temperature (°C) 37.1 (0.6) 36.9 (0.6) NS 
Arterial pH 7.36 (0.07) 7.40 (0.06) 0.013 
Noradrenaline dose (μg/kg/min) 0.40 (0.43) 0.28 (0.33) 0.009 
Lactate (mmol/L) 1.5 [1.2–3.0] 1.5 [1.2–2.1] NS 
SOFA 10 [7–11] 9 [7–12] NS 




Individual changes in main proinflammatory cytokines are shown in Figure 12, 
and anti-inflammatory cytokines in Figure 13. While high individual variability 
was noted, no significant differences before and after HVHDF were observed in 
the measured cytokines (Table 12). The mean values of most pro- and anti-
inflammatory cytokines were substantially higher than those of healthy 
volunteers (Karu et al. 2013), indicating the presence of systemic inflammatory 
response in our patients (Table 13). The ratios of pro- and anti-inflammatory 
mediators (IL-10/IL-6 and IL-10/TNFα ) were not influenced by HVHDF. 
 
 
Figure 12. Values of main proinflammatory cytokines before and after high volume 






Figure 13. Values of main anti-inflammatory cytokines before and after high volume 
haemodiafiltration (HVHDF). The lines represent single patient values. 
 
 
Table 12. Cytokine and growth factor concentrations before and after HVHDF. 
Marker Pre-HVHDF Post-HVHDF p 
IL-1α 0.2 (0.15–0.31) 0.15 (0.11–0.24) NS 
IL-1β 1.69 (1.35–2.85) 2.34 (1.19–3.27) NS 
IL-2 1.69 (1.55–1.95) 1.76 (1.41–2.05) NS 
IL-4 1.99 (1.29–3.8) 1.86 (1.36–3.03) NS 
IL-6 263.06 (119.11–866.97) 188.44 (71.04–537.83) NS 
IL-8 92.43 (19.16–198.35) 62.25 (30.92–198.35) NS 
IL-10 6.9 (1.81–9.24) 4.22 (2,74–26.8) NS 
TNF-α 7.04 (5.56–15.46) 6.69 (5.2–10.88) NS 
IFN-γ 0.23 (0.14–1.26) 0.25 (0.16–1,26) NS 
VEGF 27.41 (13.66–52.01) 27.23 (13.26–32.48) NS 
EGF 0.87 (0.82–1.04) 0.9 (0.79–1.13) NS 





Table 13. Concentrations of cytokines in patients with severe sepsis and septic shock 
and in healthy volunteers (Karu et al. 2013). Values are presented as median 
(interquartile range). 
 Study patients (n=19) Healthy volunteers 
(n=39)* 
p 
IL-1  (pg/mL) 0.20 (0.15–0.31) 0.10 (0.07–0.21) 0.001 
IL-1  (pg/mL) 1.69 (1.35–2.85) 0.66 (0.47–0.93) 0.001 
IL-2 (pg/mL) 1.69 (1.55–1.95) 1.67 (1.10–2.36) 0.004 
IL-4 (pg/mL) 1.99 (1.29–3.8) 1.38 (1.09–1.78) 0.093 
IL-6 (pg/mL) 263.06 (119.11–866.97) 0.73 (0.57–1.00) <0.001 
IL-8 (pg/mL) 92.43 (19.16–198.35) 6.63 (5.13–8.04) <0.001 
IL-10 (pg/mL) 6.9 (1.81–9.24) 0.64 (0.51–0.80) <0.001 
TNF  (pg/mL) 7.04 (5.56–15.46) 2.89 (2.49–3.86) <0.001 
IFN  (pg/mL) 0.23 (0.14–1.26) 1.37 (1.24–1.74) 0.117 
* Data from I. Karu 
 
5.6.3 Sublingual microcirculation 
The videos of sublingual microcirculation were recorded in ten patients and 
were analysable in nine. In one patient the quality was poor because of pressure 
artefacts and over lighting. No significant effects were observed on measured 
microcirculatory parameters (Table 14). 
 
Table 14. Sublingual microcirculatory parameters before and after HVHDF. 
Parameter Before HVHDF After HVHDF p 
Total vascular density 19.4 (16.5–24.8) 21.8 (18.1–26.3) 0.139 
Perfused vessel density 18.6 (15.9–22.5) 19.8 (17.7–22.9) 0.173 
Proportion of perfused vessels 93.0 (88.8–95.7) 94.4 (90.3–97.1) 0.515 
Microvascular flow index 2.8 (2.7–3.0) 2.9 (2.8–3.0) 0.074 
DeBacker score 11.4 (9.9–14.7) 13.2 (11.1–15.2) 0.214 
Data presented as median and interquartile range.  
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6. GENERAL DISCUSSION 
 6.1 Pharmacokinetics of β-lactam antibiotics  
during high volume haemodiafiltration  
in patients with septic shock 
We demonstrated that in patients with severe sepsis and septic shock with acute 
kidney injury the total body clearance of both doripenem and piperacillin during 
HVHDF was about twice slower than in healthy volunteers with normal renal 
function: doripenem clearance 6.8 L/h vs. 14.6 L/h (Cirillo et al. 2009) and 
piperacillin clearance 6.9 L/h vs 15.3 L/h (Tjandramaga et al. 1978). Whether 
the results of the present study can be extrapolated to the recommendations for 
other carbapenems during HVHDF, remains speculative. The chemical cha-
racteristics and PK of meropenem are very close to doripenem (similar terminal 
elimination half-life, low protein binding, predominantly renal elimination and 
metabolism via hydrolysis of the beta-lactam ring to a pharmacologically 
inactive metabolite) therefore, it is rational to expect their similar behaviour 
also in the setting of HVHDF.  
This finding is in contrast with common, yet untested belief that applying 
very high filtration volumes results in very high antibiotic clearance. Both 
antibiotics are significantly eliminated by RRT and while the elimination rate 
depends on the dose of haemo(dia)filtration (Valtonen et al. 2001, Ohchi et al. 
2011, Jamal et al. 2014b, Bauer et al. 2012), other RRT settings like blood flow 
rate, and pre- or postfilter substitution have influence as well. While compared 
to patients with severe renal impairment undergoing RRT in conventional doses 
of 1–2 L/h in predilution mode, total body clearance of the antibiotics in our 
study patients was much higher (Roberts et al. 2014d, Bauer et al. 2012, Asin-
Prieto et al. 2014). The difference was smaller, when compared to the setting 
where substitution fluid was administered post filter (Cirillo et al. 2011, 
Varghese et al. 2014). Prefilter dilution of the blood results in decreased 
substance clearance (Ronco et al. 2000), which might explain why the clearance 
of the both studied antibiotics in our study was only slightly higher than in 
patients undergoing CVVHDF with much smaller filtration volumes. Yet, even 
in similar RRT settings with postfilter substitution, extracorporeal clearance of 
β-lactams has been found highly variable with decreasing effluent-to-plasma 
concentration ratio with increasing effluent rate (Roberts DM et al. 2015).  
Of note, the PK of hydrophilic antibiotics is much influenced by patient 
factors like residual renal function and severity of illness (Jamal et al. 2015b). 
Roberts and colleagues found that while proportion of systemic clearance due to 
RRT varied widely between patients and occasions, the dose of haemodia-
filtration did not influence the total body clearance or volume of distribution of 
β-lactam antibiotics (Roberts DM et al. 2015). One of the reasons for this might 
be variable residual renal function of the patients. It has been described that 
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with better renal clearance of creatinine the proportion of extracorporeal 
clearance of β-lactam antibiotics decreases, and the sum effect is increased total 
body clearance of the drug (Arzuaga et al. 2005, Asin-Prieto et al. 2014). Other 
possible explanation of such observation include physiological changes typical 
to critical illness, like interstitial fluid accumulation, hypoalbuminaemia, 
disturbed (micro)circulation and liver function (Roberts DM et al. 2012). 
 
 
 6.2 Pharmacokinetics and pharmacodynamics  
of tazobactam 
Sufficient levels of beta-lactamase inhibitor are needed to ensure treatment 
efficacy and even more importantly to avoid amplification of resistant mutants 
over time (Lister et al. 1997, Louie et al. 2012). In our study the total body 
clearance of tazobactam was slower compared to piperacillin. Simulated median 
tazobactam concentrations were well above 4 mg/L, the concentration used for 
in vitro piperacillin/tazobactam susceptibility testing (EUCAST 2014). 
Modelled time-concentration profiles suggest very high steady state levels in 
some patients. While some studies show accumulation of tazobactam on RRT 
(Mueller et al 2002, Asin-Prieto et al. 2014), this was not the case during 
HVHDF. However, high steady state levels, seen in some patients, rise concern 
about potential toxicity. Tazobactam has been shown to be well tolerated in 
animal experiments with no observed adverse effect level in dogs as high as 
40 mg/kg/day (European Chemical Agency 2014). No data about safe con-
centrations in humans are available, but no toxic effects have been described 
either. Avoiding high peak tazobactam concentrations would be an argument to 
prefer prolonged infusions. Decreasing tazobactam dose in relation to that of 
piperacillin might be safer yet may lead to tazobactam underdosing and 
decreased antibacterial activity of the combination (Mueller et al. 2002, Asin-
Prieto et al. 2013). 
 
 
 6.3 Are there clear benefits of prolonged  
or continuous infusion 
Numerous studies have shown better PK/PD target achievement with prolonged 
or continuous infusion of the studied antibiotics (Bhavnani et al 2005; Samtani 
et al. 2012, Asin-Prieto et al. 2014, Roberts et al 2010a, Felton et al. 2012, 
Jamal et al. 2015c).Yet, no clinical benefit from the continuous infusion of 
meropenem, piperacillin/tazobactam and ticarcillin/calulanic acid, compared to 
intermittent administration was found in a recently published randomised 
controlled trial (Dulhunty et al. 2015). For piperacillin/tazobactam, evidence 
from smaller or retrospective studies (Dulhunty et al 2013b, Lodise et al. 2007) 
and a meta-analysis of mostly nonrandomized trials (Falagas et al. 2013) 
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suggest clinical benefit; therefore we modelled piperacillin/tazobactam 
prolonged infusion. In line with other studies (Asin-Prieto et al. 2014, Roberts 
et al 2010a, Felton et al. 2012, Jamal et al. IJAA 2015c) we found that this 
method of delivery ensures better PK/PD target attainment. For doripenem, the 
real clinical benefit from continuous infusions is even less probable. On the 
contrary, a RCT of ventilator-associated pneumonia with higher death rates in 
doripenem 4 hour infusion group compared with 1 hour infusion of imipenem 
has been published (Kollef et al. 2012). The authors state that the imipenem arm 
had less mortality because it was a 10-day course as opposed to 7-day course of 
doripenem, but we cannot rule out the possibility that low maximal con-
centration with long infusion leads to low tissue penetration and therefore even 
though circulating concentrations are above MIC, we do not have sufficient 
concentrations in the tissues. Therefore we did not model pharmacodynamic 
target attainment with doripenem. 
Starting antibacterial therapy with prolonged or continuous infusion may 
delay achieving of therapeutic drug concentrations (Rhodes et al. 2014, De 
Waele et al. 2015). This shortcoming can be overcome by providing a bolus 
loading dose, followed by prolonged infusion (De Waele et al. 2015). Some 
studies comparing continuous and intermittent administration of antibiotics 
have used loading doses (Dulhunty et al. 2013a, Roberts et al. 2009a, Dulhunty 
et al. 2015), while others have not (Roberts et al. 2009b). Loading doses should 
be used with prolonged antibiotic administration to ensure quick achievement of 
target plasma concentration and provide higher concentration gradient that 
enables more rapid achievement of therapeutic concentration at the site of 
infection (Rhodes et al. 2014, Roberts et al. 2014b) Other problems with 
prolonged infusion of antibiotics include drug stability, dead space of 
administering devices and drug to drug incompatibility (DeWaele et al. 2015). 
While meropenem is stable in 0.9% NaCl for 8 hours at temperatures less than 
25°C (Carlier et al. 2015), in glucose solutions carbapenems cannot be infused 
for longer than three hours (DeWaele et al. 2015). The problem of excessive 
dead space can be overcome by using syringe pumps, while guaranteeing a 
dedicated line for antibiotic infusion to avoid incompatibilities, may sometimes 
be difficult (De Waele et al. 2015). 
In summary, while the PK/PD targets are better met with prolonged carba-




 6.4 Dosing of doripenem and piperacillin/tazobactam 
during high volume haemodiafiltration 
For PK/PD target we chose 50%T>MIC, which for β-lactam antibiotics has 
been associated with clinical cure in intensive care patients (Roberts et al. 
2014c). For both antibiotics, doses recommended by the manufacturer (EMA, 
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 6.5 Tissue perfusion during high volume 
haemodiafiltration 
Since the landmark study by Ronco and colleagues showing better survival of 
critically ill patients with higher filtration volumes (Ronco et al. 2000), high 
volume haemofiltration has been used in patients with septic shock in order to 
achieve haemodynamic stabilisation and restore homeostasis. Pulse high volume 
haemofiltration has been proposed as salvage therapy for patients in severe 
septic shock, whose haemodynamics cannot be stabilised with conventional 
therapy (Honore et al. 2000, Cornejo et al. 2006). We found significant decrease 
of norepinephrine dose requirement during extended high volume haemo-
diafiltration in patients with septic shock despite negative fluid balance in most 
patients. This finding is in line with other experimental (Bellomo et al. 2000, 
Yekebas et al. 2002, Sykora et al. 2009) and clinical studies (Honore et al. 2000, 
Cole et al. 2001, Joannes-Boyau et al. 2004, Cornejo et al. 2006, Boussekey et 
al. 2008, Chu et al. 2013). However, a recent randomized multicentre study, 
comparing continuous haemofiltration in the dose of 35 ml/kg/h to 70 mL/kg/h 
(Joannes-Boyau 2013), did not show any haemodynamic or survival benefit 
from higher filtration volumes, yet the study was underpowered, recruiting 140 
patients instead of 460 required from power calculation. 
While the increase on blood pressure during HVHF occurs due to increased 
vascular resistance rather than increased cardiac output (Cornejo et al. 2006), 
disturbances of microcirculation might be aggravated (Sykora et al. 2009). Yet, 
Doribax; EPAR; Pfizer Ltd. 2013) for adult patients with normal renal function, 
ensured > 50%T>MIC for susceptible bacteria and could be recommended 
during extended daily HVHDF. As both antibiotics are predominantly used to 
treat infections caused by more resistant bacteria like Pseudomonas or ESBL-
producing enterobacteria (Harris et al. 2015), and severe sepsis can induce 
immunosuppression (Angus et al. 2013), higher doses may be needed to achieve 
clinical cure and avoid resistance development.  
Similar to other studies of critically ill patients (Bauer et al. 2012, Roberts et 
al. JAC 2014, Asin-Prieto et al. 2014, Roberts DM et al. 2015) we found high 
inter-patient variability in doripenem, piperacillin and tazobactam PK para-
meters, which may lead to underdosing or toxicity in some patients. Indi-
vidualised dosing for these patients has been recommended (Roberts et al. 
2014a, Jamal et al. 2015b). For individualised dose calculations mathematical 
modelling is one possibility. Yet modelling is extremely complicated due to 
huge number of patient and RRT variables with varying magnitude of influence 
involved (Jamal 2015b, Roberts DM 2015). At present, therapeutic drug 
monitoring (TDM) seems to be the most promising method for ensuring that 
antibiotic therapeutic targets are achieved in critically ill patients receiving RRT 
(Roberts DM 2015). 
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in line with other studies (Ruiz et al. 2010) we found no negative influence of 
HVHDF on microcirculation despite fluid removal during the procedure. The 
patients were volume resuscitated before the study inclusion and had micro-
circulation indices close to normal (Maddison et al. 2014). 
 
 
 6.6 Removal of cytokines by high volume 
haemodiafiltration 
As cytokines are water soluble molecules with molecular mass of 5 kDa to 60 
kDa, circulating freely in plasma, a wide range of pro and anti-inflammatory 
cytokines with molecular mass below the membrane cut-off can be removed by 
ultrafiltration (Rimmele et al. 2012). Yet, significant amounts of cytokines in 
ultrafiltrate and/or significant decrease in plasma cytokine concentration have 
been shown in few studies (Sanchez-Izquierdo et al. 1997, Cole et al. 2001, 
Ghani et al. 2006, Peng et al. 2010, Chu et al. 2013). A meta-analysis of animal 
studies concluded that high volume haemofiltration with conventional 
haemofilters effectively removes IL-6 and IL-10, while TNF-α is not removed 
due to molecular mass above membrane cut-off values (Atan 2013a).  
For the polyarylethersulfone (PAES) haemofilter, used in this study, 
removal of small molecular-weight proteins with molecular mass up to 24 kDa 
via both filtration and adsorption has been shown in ESRD patients (Ouseph et 
al. 2008). No data could be found for the use of Polyflux 210H in septic shock 
patients. 
As the efficacy of cytokine removal by HVHF is questionable other 
mechanisms potentially responsible for the decrease in norepinephrine require-
ments, induced by HVHF are cooling, which was not the case in our study, 
removal of unmeasured organic anions (Bellomo et al. 2013) or removal of 
other mediators, responsible for hypotension and vasodilation, like prosta-
glandins, leukotrienes (Yokoyama et al. 2009), complement factors (Cole et al. 
2001) or myocardial depressants (Blake et al. 1996). Increase in pH might also 
have been responsible for the decrease of vasopressor requirement. Yet this 
explanation is unlikely, as Bellomo and colleagues comparing different intensities 
of continuous haemofiltration (CHF) found similar correction of acidosis, but 
greater increase in mean arterial pressure and decrease in norepinephrine 
requirements in high intensity CHF group (Bellomo et al. 2013). 
 
 
6.7 Methodological considerations 
We performed a single dose pharmacokinetic study with rich precisely timed 
and documented sampling schedule that allows accurate description of plasma 
concentration-time profiles and efficient population PK parameter estimation of 
doripenem, piperacillin and tazobactam during HVHDF. It has been shown that 
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sampling schedule has influence on the efficiency of population PK parameter 
estimation with inaccurate estimates with low number of data points per 
individual (al Banna et al. 1990). Yet we did not measure steady state 
concentrations of the antibiotics. In one study the total body clearance and 
volume of distribution of piperacillin has been shown to be lower after multiple 
doses than after a single dose (Capellier et al. 1998). Other studies have not 
reached similar results (Roberts et al. 2009a, Jamal et al. 2015c). Still, large 
intra-individual day-to-day variability in total body clearance and RRT 
clearance of β-lactam antibiotics has been shown, making empirical dosing of 
these drugs extremely complicated and suggesting the need of therapeutic drug 
monitoring (Roberts DM et al. 2015). Dynamic changes in physiology of 
critical illness, especially in residual renal function may contribute to these 
observations (Roberts DM et al. 2015). 
We were not able to describe the extent of extracorporeal clearance of the 
studies antibiotics as it was not possible to get ultrafiltrate/dialysate samples 
from the tubing. Still, our data on total exposition to the drugs and total body 
clearance allow dose recommendations in this population. 
A two-compartment linear model fitted both the doripenem and piperacillin/ 
tazobactam data best. Previous data suggest that piperacillin elimination may 
have a significant saturable component in healthy volunteers, mostly due to 
saturable renal tubular secretion (Tjandramaga et al. 1978, Bergan et al. 1982, 
Landersdorfer et al. 2012). Yet the influence of saturable renal elimination for 
clinically relevant dosage regimens is thought to be insignificant in healthy 
volunteers (Landersdorfer et al. 2012) and in critically ill patients (Roberts et al. 
2009a). Other studies of the PK of piperacillin in critically ill patients 
undergoing RRT have also found two-compartment linear model best fitted to 
the data (Giron et al. 1981, van der Werf et al. 1997, Asin-Prieto et al. 2013). 
We were not able to draw conclusions about the impact of patient or 
HVHDF characteristics on the pharmacokinetics of doripenem, piperacillin and 
tazobactam. This was beyond the scope of the study. As our aim was to define 
dosing recommendations, we used a well standardised HVHDF protocol. Also, 
during haemodiafiltration both diffusive and convective clearances play 
important role in the elimination of small molecules like the studied antibiotics. 
Both clearances may be non-linear at higher effluent rates (Roberts DM et al. 
2015) and varying proportions of dialysate and ultrafiltrate flows may influence 
solute clearance variably (Brunet et al. 1999). 
Future research could be directed to using therapeutic drug monitoring to 
identify covariates that influence the PK of antibiotics in critically ill patients, in 
order to enable model-based individual dosing recommendations, and further, 
assessing the influence of the individual dosing recommendations on clinical 
efficacy, safety and possibly on resistance development.   
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7 CONCLUSIONS 
1. Application of extended HVHDF for treatment of acute kidney injury results 
in considerable removal of doripenem in septic shock patients. Doses of 500 
mg every 8 h are necessary for treatment of susceptible bacteria in 
immunocompetent patients during daily HVHDF, if the sessions are 
extended to meet the standards of continuous renal replacement therapy. 
Aiming for more than 50% of time above MIC and/or treating infections 
with less susceptible micro-organisms, dosing regimens up to 1000 mg 
every 8 h could be advocated for optimal efficacy during HVHDF. 
2. For bactericidal PK/PD target attainment piperacillin/tazobactam doses of 
4/0.5 g every 8 hours appear appropriate in severe sepsis and septic shock 
patients with minimal residual renal function during HVHDF. This dosing 
regimen is sufficient for treating infections caused by intermediately 
susceptible bacteria. Further evaluation of the potential toxicity of 
tazobactam is warranted. 
3. Due to high inter-individual variability and insufficient data available for 
sound individual dose modelling in patients with severe sepsis and septic 
shock on HVHDF, dose adjustment based on therapeutic drug monitoring of 
the β-lactam concentrations may be the preferred way to improve therapeutic 
target attainment. 
4. The single-centre study suggests that extended intermittent HVHDF results 
in decrease of norepinephrine requirement and preserved microcirculation in 
patients with severe sepsis and septic shock. Haemodynamic improvement is 
not associated with decrease in circulating cytokine levels. Further research 
focusing on the identification of the mechanisms underlying these findings 
may help to potentiate these effects in order to improve treatment outcomes. 
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9. SUMMARY IN ESTONIAN 
Suuremahuline hemodiafiltratsioon raske sepsise ravis –  
toime antibiootikumide farmakokineetikale ning  
süsteemsele põletikureaktsioonile 
Sepsis – organismi ülepiiriline reaktsioon infektsioonile – ja selle kõige raskemad 
vormid, raske sepsis (infektsioonist tingitud äge(dad) organpuudulikkus(sed)) ja 
septiline šokk (raskele sepsisele lisandunud hüpotensioon, mis ei möödu infu-
sioonraviga) (Dellinger et al. 2013), on oluline tervishoiuprobleem (Angus et al. 
2013). Raske sepsise esinemissagedus suureneb (Brun Buisson et al. 2004). 
Kuigi surevus on viimase kümnendi jooksul vähenenud, jääb see siiski kõrgeks 
(Brun Buisson et al. 2004, Dombrovskiy et al. 2007). Äge neerupuudulikkus, 
mis sageli raske sepsise tüsistusena tekib, on iseseisev surma riskifaktor (Brun 
Buisson et al. 2004). 
Sepsise ravi võtmeküsimusteks on adekvaatne antibakteriaalne ravi, kiire 
kolde kontroll ja ülepiirilise immunoloogilise reaktsiooni pidurdamine. Anti-
bakteriaalse ravi hiline algus või vale antibiootikumi valik viivad sepsisehaigete 
surevuse suurenemisele (Kumar et al. 2006). Süsteemse põletikureaktsiooni 
pidurdamine on niisama oluline, kuid raske saavutada selle reaktsiooni väga 
keeruka olemuse ja osalevate mediaatorite suure arvu tõttu. Viimasel 15 aastal 
on immuunhomöostaasi taastamiseks kasutatud mediaatorite kehavälist eemal-
damist neeruasendusravi abil (Ronco et al. 2004). Keskmiste molekulide, nagu 
tsütokiinid eemaldamise efektiivsus sõltub rakendatud neeruasendusravi meeto-
dist, aga ka filtri omadustest ja ravi mahust (Ricci et al. 2006a, Cerda et al. 
2009). Kliinilised ja eksperimentaalsed andmed näitavad ägeda neerupuudu-
likkusega sepsisehaigete paremat elulemust neeruasendusravi mahtude suurene-
misega (Honore et al. 2000, Schiffl et al. 2002, Cornejo et al. 2006, Bouman et 
al. 2007). Andmed on siiski mõneti vastuolulised, sest hiljutine randomiseeritud 
kontrollitud uuring sellisele tulemusele ei jõudnud (Joannes-Boyau et al. 2013). 
Kron-i ja kaastöötajate avaldatud esmased tulemused lubavad oletada, et 
suuremahuline hemodiafiltratsioon spetsiifilises Ultracontrol režiimis on seotud 
haiguse raskuse järgi prognoositust suurema elulemusega (Kron et al. 2011). 
Erinevalt tavalisest rõhu- või mahukontrollitud hemofiltratsioonist tiitrib ultra-
control režiim diafiltratsiooni ajal hemofiltri transmembraanset rõhku nii, et 
saavutatakse optimaalsed tingimused (maksimaalne filtratsioonimaht mada-
laima võimaliku rõhu juures). Pakendatud asenduslahuste asemel kasutatakse 
läbi filtrite puhastatud vett, millele lisatakse elektrolüüdid. See muudab meetodi 
võimalikuks, kulud ei ületa oluliselt tavalise hemodialüüsi kulusid (Kron et al. 
2011). 
Kuigi potentsiaalselt efektiivne süsteemse põletikureaktsiooni ravis, võib 
suuremahuline hemodiafiltratsioon organismist eemaldada liigselt antibiooti-
kume, mistõttu nende eluliselt oluliste ravimite kontsentratsioon vereplasmas ja 
kudedes langeb alla vajaliku, vähendades või elimineerides protseduurist saadava 
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potentsiaalse kasu (Jamal et al. 2014b). Teisest küljest võib annuste kontrolli-
matu suurendamine põhjustada kõrvaltoimeid (Roberts DM et al. 2012).  
Beeta-laktaamantibiootikumide farmakokineetikat on uuritud erinevate 
neeruasenduravi meetodite ajal ja on leitud, et hemo(dia)filtratsioon eemaldab 
neid olulises hulgas, seejuures sõltub eemaldamine neeruasenduravi meetodist 
ja mahust (Jamal et al. 2014b). Suuremahulise hemodiafiltratsiooni ajal ei ole 




Uurimistöö üldiseks eesmärgiks oli kirjeldada suuremahulise hemodiafiltrat-
siooni mõju kahe β-laktaam-antibiootikumi farmakokineetikale ja süsteemsele 




1. Kirjeldada doripeneemi farmakokineetikat suuremahulise hemodiafiltrat-
siooni ajal, et määrata optimaalsed annused selle neeruasendusravi meetodi 
jaoks 
2. Kirjeldada piperatsilliini ja tasobaktaami farmakokineetikat suuremahulise 
hemodiafiltratsiooni ajal, et määrata optimaalsed annused selle neeruasen-
dusravi meetodi jaoks 
3. Teha kindlaks, kas suuremahuline hemodiafiltratsioon mõjutab seerumi 
tsütokiinide profiili ja/või omab efekti raske sepsise ja septilise šoki haigete 
arteriaalsele vererõhule või keelealusele mikrotsirkulatsioonile 
 
 
Patsiendid ja metoodika 
Käesolev uurimus põhineb SA Tartu Ülikooli Kliinikumi üldintensiivravi osa-
konnas 01.09.2011 – 25.06.2014 läbi viidud uuringul. 
Uuringusse kaasati täiskasvanud patsiendid, kellel oli raske sepsis või 
septiline šokk (Bone et al. 1992) sellest tingitud ägeda neerupuudulikkusega, 
kes raviarsti hinnangul vajasid neeruasendusravi suuremahulise hemodiafiltrat-
siooniga, kellele oli paigaldatud arteri kanüül ja kelle lähedane oli andnud 
informeeritud nõusoleku patsiendi uuringus osalemiseks. Suuremahuline hemo-
diafiltratsioon viidi läbi ultracontrol režiimis eellahjendusega (Kron et al. 
2011). Verevoolu kiirus hoiti 200 mL/min ja dialüsaadi/asenduslahuse voolu-
kiirus 500–650 mL/min. Hemodiafiltratsiooni planeeritud kestvus oli 10 tundi. 
Doripeneemi esimese doosi farmakokineetika uuringusse kaasatud üheksale 
patsiendile manustati 500 mg doripeneemi ühetunnise infusioonina ja võeti 
vereplasma proovid vahetult pärast infusiooni lõppemist ja iga 30 minuti ning 
hiljem iga tunni järel kaheksa tunni jooksul. Piperatsilliin/tasobaktaami uurin-
gusse kaasatud 10 patsiendile manustati 4g piperatsilliini koos 0,5g taso-
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baktaamiga 30-minutilise infusioonina ja vereplasma proovid koguti vahetult 
infusiooni lõppedes ja edasi iga 30 minuti ning hiljem iga tunni järel kaheksa 
tunni jooksul. Kahel patsiendil koguti vereproovid ka pärast hemodiafiltrat-
siooni lõppu 12 ja 24 tundi ravimi manustamisest. Doripeneemi, piperatsilliini 
ja tasobaktaami kontsentratsioonid määrati kõrgsurve vedelikkromatograafia ja 
tandem mass-spektomeetria abil. Saadud plasmakontsentratsioonide alusel 
modelleeriti doripeneemi, piperatsilliini ja tasobaktaami populatsiooni- far-
makokineetika parameetrid suuremahulise hemodiafiltratsiooni ajal ning viidi 
läbi Monte Carlo simulatsioon suuremahulise hemodiafiltratsiooni ajal vajalike 
doripeneemi ja piperatsilliini annuste leidmiseks. Kõigil mõlemasse uuringusse 
kaasatud patsientidel (kokku 19) registreeriti arteriaalne vererõhk, vasopres-
sorite annused ja muud kliinilised parameetrid enne ja pärast hemodiafiltrat-
siooni, samuti koguti vereseerumi proovid tsütokiinide kontsentratsiooni määra-





Doripeneemi maksimaalsed plasmakontsentratsioonid olid väga suure varieeru-
vusega: 12,4–40,7 mg/L. Doripeneemi tase plasmas ületas tundlike bakterite 
minimaalset inhibeerivat kontsentratsiooni (MIC) 1 mg/L kogu määramis-
perioodi ajal kaheksal haigel üheksast. Doripeneemi kogukliirens ägeda neeru-
puudulikkusega septilises šokis patsientidel oli suuremahulise hemodiafiltrat-
siooni ajal umbes kaks korda aeglasem kui tervetel vabatahtlikel. Tundlike 
bakterite poolt põhjustatud infektsioonide raviks nendel patsientidel selle 
neeruasendusravi ajal sobivad annused 500 mg iga 8 tunni järel. Kui ravitakse 
mõõdukalt tundlike bakterite poolt põhjustatud infektsioone või on tegemist 
neutropeenias patsientidega, võib olla vajalik annuste suurendamine. 
Piperatsilliini ja tasobaktaami maksimaalsete kontsentratsioonide varieeru-
vus oli samuti suur: piperatsilliinil 197
63,9 mg/L. Ka piperatsilliini kogukliirens ägeda neerupuudulikkusega septilises 
šokis patsientidel oli tervetest vabatahtlikest umbes kaks korda aeglasem. 
Suuremahulise hemodiafiltratsiooni foonil sobivad sellele patsientide grupile 
piperatsilliini annused 4g iga 8 tunni järel nii tundlike kui ka mõõdukalt 
tundlike bakterite poolt põhjustatud infektsioonide raviks. Standardses kombi-
natsioonis 4g piperatsilliiniga koos manustatav 0,5 grammi tasobaktaami 
kindlustab vajalikuks ajaperioodiks selle β-laktamaasi inhibiitori vajaliku kont-
sentratsiooni. Samas ulatusid modelleeritud tasobaktaami kontsentratsioonid 
mõnel juhul väga kõrgete väärtusteni, mis võib tõsta ohutuse küsimuse. 
Keskmise vererõhu 70–80 mmHg säilitamiseks vajalik noradrenaliini annus 
vähenes suuremahulise hemodiafiltratsiooni ajal oluliselt [0,40 (0,43) μg/kg/min 
→ 0,28 (0,33) μg/kg/min, p=0,009]. Määratud tsütokiinide kontsentratsioonides 
ega keelealuse mikrotsirkulatsiooni parameetrites olulisi muutusi ei tekkinud. 
 
,8–356,4 mg/L ja tasobaktaamil 22,6–
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Järeldused 
1. Doripeneemi annused 500 mg iga 8 tunni järel sobivad tundlike bakterite 
põhjustatud infektsioonide raviks septilises šokis patsientidel igapäevase 
suuremahulise hemodiafiltratsiooni ajal, kui protseduuri pikendatakse 
vähemalt 20 tunnini ööpeäevas. Immuunsupressiivsetel patsientidel või 
mõõdukalt tundlike bakterite poolt põhjustatud infektsioonide ravis võib olla 
vajalik annuste suurendamine. 
2. Piperatsilliin/tasobaktaami annused 4,5g iga 8 tunni järel on sobivad nii 
tundlike kui ka mõõdukalt tundlike bakterite põhjustatud infektsioonide 
raviks septilises šokis patsientidel igapäevase suuremahulise hemodiafiltrat-
siooni ajal. Tasobaktaami võimalikku toksilisust oleks vaja edasistes uurin-
gutes hinnata. 
3. Doripeneemi ja piperatsilliin/tasobaktaami annused tuleks võimalusel igale 
patsiendile määratud plasmakontsentratsioonide alusel individuaalselt 
kohandada.  
4. Suuremahulise hemodiafiltratsiooni rakendamine ägeda neerupuudulikku-
sega septilises šokis patsientidel vähendas arteriaalse vererõhu säilitamiseks 
vajalikku noradrenaliini annust. Hemodünaamika paranemine ei olnud 
seotud tsirkuleerivate tsütokiinide kontsentratsiooni vähenemisega, keele-
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